Skip to main content
Psychedex
Sources
38
35 moderate · 3 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
93
73verified7partial9inconclusive4not supported

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
Apr 26, 2026 · pipeline-v5
Values approved
183/183 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

insufflatedtrace

FieldPublishedAI ProposedConfidence
Threshold1 mg1 mglow
Low1–5 mg1–5 mglow
Common5–15 mg5–15 mglow
Strong15–25 mg15–25 mglow
Heavy25+ mg25+ mglow
Editorial

No published human dose-response data. Values derived from community harm reduction databases (PsychonautWiki, Bluelight). The Di Trana et al. 2025 naturalistic study used 10 mg and 20 mg intranasal doses with measurable pharmacological effects, consistent with these ranges. Widened spreads to account for uncertainty.

Reasoning

No published human dose-response data. Values derived from community harm reduction databases (PsychonautWiki, Bluelight). The Di Trana et al. 2025 naturalistic study used 10 mg and 20 mg intranasal doses with measurable pharmacological effects, consistent with these ranges. Widened spreads to account for uncertainty.

Evidence basis: community_consensus_large

smokedtrace

FieldPublishedAI ProposedConfidence
Threshold1 mg1 mglow
Low1–4 mg1–4 mglow
Common4–10 mg4–10 mglow
Strong10–20 mg10–20 mglow
Heavy20+ mg20+ mglow
Editorial

No published human dose-response data for smoked route. Values derived from community harm reduction databases. Smoked route expected to have higher bioavailability and faster onset than insufflated, with lower effective doses at each tier. No controlled PK data for this route.

Reasoning

No published human dose-response data for smoked route. Values derived from community harm reduction databases. Smoked route expected to have higher bioavailability and faster onset than insufflated, with lower effective doses at each tier. No controlled PK data for this route.

Evidence basis: community_consensus_large

oraltrace

FieldPublishedAI ProposedConfidence
Threshold2 mg2 mglow
Low2–5 mg2–5 mglow
Common5–15 mg5–15 mglow
Strong15–25 mg15–25 mglow
Heavy25+ mg25+ mglow
Editorial

No published human oral PK or dose-response data. Values derived from community harm reduction databases. Oral route expected to have slower onset and potentially lower bioavailability than insufflated, but similar dose ranges based on community reports. All values require editorial verification.

Reasoning

No published human oral PK or dose-response data. Values derived from community harm reduction databases. Oral route expected to have slower onset and potentially lower bioavailability than insufflated, but similar dose ranges based on community reports. All values require editorial verification.

Evidence basis: community_consensus_large

Duration

smoked

FieldPublishedAI ProposedConfidence
Peaktrace3–10 minutes3–10 minuteslow
Editorial

Community database data indicates peak of 3-6 minutes for smoked route. Widened to 3-10 minutes to account for individual variation.

Reasoning

Community database data indicates peak of 3-6 minutes for smoked route. Widened to 3-10 minutes to account for individual variation.

Evidence basis: community_consensus_large

Onsettrace0.3–1 minutes0.3–1 minuteslow
Editorial

Community reports indicate near-instantaneous onset (20-60 seconds) for smoked α-PVP. Taffe et al. 2021 confirmed abbreviated inhalation timelines in animal models.

Reasoning

Community reports indicate near-instantaneous onset (20-60 seconds) for smoked α-PVP. Taffe et al. 2021 confirmed abbreviated inhalation timelines in animal models.

Evidence basis: community_consensus_large

Come uptrace0.5–3 minutes0.5–3 minuteslow
Editorial

Community reports. Rapid come-up consistent with pulmonary absorption kinetics.

Reasoning

Community reports. Rapid come-up consistent with pulmonary absorption kinetics.

Evidence basis: community_consensus_large

Offsettrace15–45 minutes15–45 minuteslow
Editorial

Community reports. Rapid decline following brief peak is consistent with Taffe et al. 2021 animal data showing abbreviated inhalation duration.

Reasoning

Community reports. Rapid decline following brief peak is consistent with Taffe et al. 2021 animal data showing abbreviated inhalation duration.

Evidence basis: community_consensus_large

Totaltrace20–60 minutes20–60 minuteslow
Editorial

Community reports for total subjective duration of smoked α-PVP. Abbreviated vs insufflated route, consistent with Taffe et al. 2021 inhalation data.

Reasoning

Community reports for total subjective duration of smoked α-PVP. Abbreviated vs insufflated route, consistent with Taffe et al. 2021 inhalation data.

Evidence basis: community_consensus_large

After effectstrace1–4 hours1–4 hourslow
Editorial

Community reports. Per-dose aftereffects are relatively short but compound substantially during binge sessions.

Reasoning

Community reports. Per-dose aftereffects are relatively short but compound substantially during binge sessions.

Evidence basis: community_consensus_large

insufflated

FieldPublishedAI ProposedConfidence
Onsettrace2–10 minutes2–10 minutesmedium
Editorial

Di Trana et al. 2025 measured Tmax at 47-60 minutes intranasal, indicating first effects emerge well before peak. Community reports consistent with 2-10 minute onset for insufflated route.

Reasoning

Di Trana et al. 2025 measured Tmax at 47-60 minutes intranasal, indicating first effects emerge well before peak. Community reports consistent with 2-10 minute onset for insufflated route.

Evidence basis: community_consensus_large

Come uptrace10–30 minutes10–30 minuteslow
Editorial

Inferred from Tmax data (47-60 min) and community reports. Come-up period bridges onset to peak.

Reasoning

Inferred from Tmax data (47-60 min) and community reports. Come-up period bridges onset to peak.

Evidence basis: community_consensus_large

Peaktrace45–90 minutes45–90 minuteslow
Editorial

Community reports. Tmax at 47-60 min supports peak occurring in this window. Duration of peak phase not formally measured.

Reasoning

Community reports. Tmax at 47-60 min supports peak occurring in this window. Duration of peak phase not formally measured.

Evidence basis: community_consensus_large

Offsettrace1–2 hours1–2 hourslow
Editorial

Community reports for insufflated stimulant cathinones. No published data for α-PVP offset duration.

Reasoning

Community reports for insufflated stimulant cathinones. No published data for α-PVP offset duration.

Evidence basis: community_consensus_large

Totaltrace2–5 hours2–5 hourslow
Editorial

Community reports for total subjective duration of insufflated α-PVP. No controlled human data exist for this parameter.

Reasoning

Community reports for total subjective duration of insufflated α-PVP. No controlled human data exist for this parameter.

Evidence basis: community_consensus_large

After effectstrace2–6 hours2–6 hourslow
Editorial

Community reports. Residual stimulant aftereffects (insomnia, low mood) persist beyond subjective experience.

Reasoning

Community reports. Residual stimulant aftereffects (insomnia, low mood) persist beyond subjective experience.

Evidence basis: community_consensus_large

oral

FieldPublishedAI ProposedConfidence
Onsettrace15–45 minutes15–45 minuteslow
Editorial

Community reports for oral α-PVP. No published human oral PK data exist.

Reasoning

Community reports for oral α-PVP. No published human oral PK data exist.

Evidence basis: community_consensus_large

Come uptrace15–45 minutes15–45 minuteslow
Editorial

Community reports. Oral come-up is slower and more gradual than insufflated.

Reasoning

Community reports. Oral come-up is slower and more gradual than insufflated.

Evidence basis: community_consensus_large

Peaktrace1–2 hours1–2 hourslow
Editorial

Community reports for oral route. Expected longer peak than insufflated due to slower absorption.

Reasoning

Community reports for oral route. Expected longer peak than insufflated due to slower absorption.

Evidence basis: community_consensus_large

Offsettrace1–3 hours1–3 hourslow
Editorial

Community reports for oral stimulant cathinone offset.

Reasoning

Community reports for oral stimulant cathinone offset.

Evidence basis: community_consensus_large

Totaltrace2–6 hours2–6 hourslow
Editorial

Community reports for total oral α-PVP duration. Longer than insufflated due to slower absorption and potentially different first-pass metabolism.

Reasoning

Community reports for total oral α-PVP duration. Longer than insufflated due to slower absorption and potentially different first-pass metabolism.

Evidence basis: community_consensus_large

After effectstrace2–8 hours2–8 hourslow
Editorial

Community reports. Oral aftereffects may persist longer due to extended absorption phase.

Reasoning

Community reports. Oral aftereffects may persist longer due to extended absorption phase.

Evidence basis: community_consensus_large

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutehighhighmedium
Chronicmoderatemoderatemedium
Organs Affectedcardiovascular, kidney, skeletal_muscle, braincardiovascular, kidney, skeletal_muscle, brainmedium
Editorial

Acute: classified as high based on 34 fatal Finnish cases (Kriikku 2024), documented sympathomimetic toxidrome with rhabdomyolysis and AKI (Ross 2012, Banks 2014), and direct myotoxicity via mitochondrial Complex I inhibition (Zhou 2019). No LD50 established, but fatalities at recreational doses (with polydrug confounding) support high acute risk. Chronic: classified as moderate based on animal-only data — brain mitochondrial dysfunction at 20 mg/kg (Noruzi 2023) and sex-selective neuroinflammation (Marusich 2022). Downgraded from high because chronic evidence is entirely preclinical.

Reasoning

Acute: classified as high based on 34 fatal Finnish cases (Kriikku 2024), documented sympathomimetic toxidrome with rhabdomyolysis and AKI (Ross 2012, Banks 2014), and direct myotoxicity via mitochondrial Complex I inhibition (Zhou 2019). No LD50 established, but fatalities at recreational doses (with polydrug confounding) support high acute risk. Chronic: classified as moderate based on animal-only data — brain mitochondrial dysfunction at 20 mg/kg (Noruzi 2023) and sex-selective neuroinflammation (Marusich 2022). Downgraded from high because chronic evidence is entirely preclinical.

Evidence basis: published_case_series

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicallowlowhigh
Psychologicalhighhighhigh
Compulsive Redosinghighhighhigh
Dose Escalationhighhighhigh
Editorial

Psychological dependence: high confidence based on 100% self-administration acquisition (Gannon 2018), supranormal reinforcing efficacy vs cocaine (Huskinson 2017), CREB pathway activation (Hataoka 2017), and extreme DAT selectivity (Persson 2024). Compulsive redosing: high based on preclinical self-administration and case report documentation. Physical dependence: classified as low — no human withdrawal characterization exists, but dopaminergic stimulant class pharmacology predicts mild physical withdrawal (fatigue, hypersomnia, dysphoria).

Reasoning

Psychological dependence: high confidence based on 100% self-administration acquisition (Gannon 2018), supranormal reinforcing efficacy vs cocaine (Huskinson 2017), CREB pathway activation (Hataoka 2017), and extreme DAT selectivity (Persson 2024). Compulsive redosing: high based on preclinical self-administration and case report documentation. Physical dependence: classified as low — no human withdrawal characterization exists, but dopaminergic stimulant class pharmacology predicts mild physical withdrawal (fatigue, hypersomnia, dysphoria).

Evidence basis: animal_study

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitymildmildlow
Symptomsfatigue, hypersomnia, dysphoria, anhedonia, increased appetite, psychomotor retardationfatigue, hypersomnia, dysphoria, anhedonia, increased appetite, psychomotor retardationlow
FatalNoNolow
Medical SupervisionNot requiredNot requiredlow
Editorial

No published human withdrawal data for α-PVP specifically. Withdrawal profile inferred from dopaminergic stimulant class (cocaine, amphetamine withdrawal literature). Expected to be primarily psychological with fatigue, anhedonia, and hypersomnia. Not life-threatening.

Reasoning

No published human withdrawal data for α-PVP specifically. Withdrawal profile inferred from dopaminergic stimulant class (cocaine, amphetamine withdrawal literature). Expected to be primarily psychological with fatigue, anhedonia, and hypersomnia. Not life-threatening.

Evidence basis: animal_study

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Builduprapidrapidlow
Half-life5 days5 dayslow
Full Reset10 days10 dayslow
Cross-tolerancescocaine, amphetamine, methamphetamine, MDPV, methylphenidatecocaine, amphetamine, methamphetamine, MDPV, methylphenidatelow
Editorial

Rapid buildup classification based on community reports of within-session tolerance and escalating doses during binge use. Half-life and reset values carried forward from existing database estimates (community consensus). Mechanism inferred from MDPV sensitization data (Duart-Castells 2019) showing DAT downregulation and ΔFosB induction. Cross-tolerance list based on shared DAT inhibition mechanism.

Reasoning

Rapid buildup classification based on community reports of within-session tolerance and escalating doses during binge use. Half-life and reset values carried forward from existing database estimates (community consensus). Mechanism inferred from MDPV sensitization data (Duart-Castells 2019) showing DAT downregulation and ΔFosB induction. Cross-tolerance list based on shared DAT inhibition mechanism.

Evidence basis: community_consensus_large

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
cardiovascular coronary artery diseasetraceabsoluteabsolutehigh
Editorial

Cardiovascular effects documented in Schindler et al. 2020 and sympathomimetic toxidrome in Banks 2014 and Ross 2012.

Reasoning

Cardiovascular effects documented in Schindler et al. 2020 and sympathomimetic toxidrome in Banks 2014 and Ross 2012.

cardiovascular uncontrolled hypertensiontraceabsoluteabsolutehigh
Editorial

Hypertension documented as component of sympathomimetic toxidrome (Banks 2014, Ross 2012). Cardiovascular effects confirmed in Schindler 2020.

Reasoning

Hypertension documented as component of sympathomimetic toxidrome (Banks 2014, Ross 2012). Cardiovascular effects confirmed in Schindler 2020.

cardiovascular cardiac arrhythmiastraceabsoluteabsolutemedium
Editorial

Cardiac arrhythmias documented as component of toxidrome requiring ICU monitoring (Banks 2014).

Reasoning

Cardiac arrhythmias documented as component of toxidrome requiring ICU monitoring (Banks 2014).

psychiatric psychotic disorderstraceabsoluteabsolutehigh
Editorial

Psychosis risk documented in Vinnikova & Severtsev 2023 and Patocka 2020.

Reasoning

Psychosis risk documented in Vinnikova & Severtsev 2023 and Patocka 2020.

psychiatric bipolar disordertraceabsoluteabsolutemedium
Editorial

Mania documented in Patocka 2020 review. DAT-mediated stimulation is established trigger for bipolar episodes.

Reasoning

Mania documented in Patocka 2020 review. DAT-mediated stimulation is established trigger for bipolar episodes.

neurological epilepsytracerelativerelativemedium
Editorial

Seizures documented in sympathomimetic toxidrome (Banks 2014, Ross 2012).

Reasoning

Seizures documented in sympathomimetic toxidrome (Banks 2014, Ross 2012).

renal chronic kidney diseasetracerelativerelativemedium
Editorial

Direct myotoxicity documented in Zhou 2019. Clinical AKI in Sutamtewagul 2014.

Reasoning

Direct myotoxicity documented in Zhou 2019. Clinical AKI in Sutamtewagul 2014.

pregnancy breastfeeding pregnancy and breastfeedingtraceabsoluteabsolutemedium
Editorial

No substance-specific data. Class-level sympathomimetic contraindication during pregnancy.

Reasoning

No substance-specific data. Class-level sympathomimetic contraindication during pregnancy.

Timeline Phases

insufflated

FieldPublishedAI ProposedConfidence
Onsettrace120–600 sec(i=0.05)120–600 sec(i=0.05)low
Editorial

Timeline derived from Di Trana et al. 2025 Tmax data (47-60 min intranasal) as the only published human PK anchor, supplemented by community duration reports. No controlled human duration studies exist. Overall duration consistent with pyrovalerone-class stimulant pharmacology.

Reasoning

Timeline derived from Di Trana et al. 2025 Tmax data (47-60 min intranasal) as the only published human PK anchor, supplemented by community duration reports. No controlled human duration studies exist. Overall duration consistent with pyrovalerone-class stimulant pharmacology.

Come uptrace600–1800 sec(i=0.35)600–1800 sec(i=0.35)low
Editorial

Timeline derived from Di Trana et al. 2025 Tmax data (47-60 min intranasal) as the only published human PK anchor, supplemented by community duration reports. No controlled human duration studies exist. Overall duration consistent with pyrovalerone-class stimulant pharmacology.

Reasoning

Timeline derived from Di Trana et al. 2025 Tmax data (47-60 min intranasal) as the only published human PK anchor, supplemented by community duration reports. No controlled human duration studies exist. Overall duration consistent with pyrovalerone-class stimulant pharmacology.

Peaktrace2700–5400 sec(i=1.00)2700–5400 sec(i=1.00)low
Editorial

Timeline derived from Di Trana et al. 2025 Tmax data (47-60 min intranasal) as the only published human PK anchor, supplemented by community duration reports. No controlled human duration studies exist. Overall duration consistent with pyrovalerone-class stimulant pharmacology.

Reasoning

Timeline derived from Di Trana et al. 2025 Tmax data (47-60 min intranasal) as the only published human PK anchor, supplemented by community duration reports. No controlled human duration studies exist. Overall duration consistent with pyrovalerone-class stimulant pharmacology.

Plateautrace3600–7200 sec(i=0.55)3600–7200 sec(i=0.55)low
Editorial

Timeline derived from Di Trana et al. 2025 Tmax data (47-60 min intranasal) as the only published human PK anchor, supplemented by community duration reports. No controlled human duration studies exist. Overall duration consistent with pyrovalerone-class stimulant pharmacology.

Reasoning

Timeline derived from Di Trana et al. 2025 Tmax data (47-60 min intranasal) as the only published human PK anchor, supplemented by community duration reports. No controlled human duration studies exist. Overall duration consistent with pyrovalerone-class stimulant pharmacology.

Resolutiontrace3600–7200 sec(i=0.20)3600–7200 sec(i=0.20)low
Editorial

Timeline derived from Di Trana et al. 2025 Tmax data (47-60 min intranasal) as the only published human PK anchor, supplemented by community duration reports. No controlled human duration studies exist. Overall duration consistent with pyrovalerone-class stimulant pharmacology.

Reasoning

Timeline derived from Di Trana et al. 2025 Tmax data (47-60 min intranasal) as the only published human PK anchor, supplemented by community duration reports. No controlled human duration studies exist. Overall duration consistent with pyrovalerone-class stimulant pharmacology.

Afterglowtrace7200–21600 sec(i=0.05)7200–21600 sec(i=0.05)low
Editorial

Timeline derived from Di Trana et al. 2025 Tmax data (47-60 min intranasal) as the only published human PK anchor, supplemented by community duration reports. No controlled human duration studies exist. Overall duration consistent with pyrovalerone-class stimulant pharmacology.

Reasoning

Timeline derived from Di Trana et al. 2025 Tmax data (47-60 min intranasal) as the only published human PK anchor, supplemented by community duration reports. No controlled human duration studies exist. Overall duration consistent with pyrovalerone-class stimulant pharmacology.

smoked

FieldPublishedAI ProposedConfidence
Onsettrace5–60 sec(i=0.10)5–60 sec(i=0.10)low
Editorial

Timeline based on community-reported smoked duration data (onset 20-60 seconds, peak 3-6 minutes) and Taffe et al. 2021 confirming abbreviated duration via inhalation vs injection in animal models. No controlled human smoked-route PK data exist.

Reasoning

Timeline based on community-reported smoked duration data (onset 20-60 seconds, peak 3-6 minutes) and Taffe et al. 2021 confirming abbreviated duration via inhalation vs injection in animal models. No controlled human smoked-route PK data exist.

Come uptrace30–180 sec(i=0.50)30–180 sec(i=0.50)low
Editorial

Timeline based on community-reported smoked duration data (onset 20-60 seconds, peak 3-6 minutes) and Taffe et al. 2021 confirming abbreviated duration via inhalation vs injection in animal models. No controlled human smoked-route PK data exist.

Reasoning

Timeline based on community-reported smoked duration data (onset 20-60 seconds, peak 3-6 minutes) and Taffe et al. 2021 confirming abbreviated duration via inhalation vs injection in animal models. No controlled human smoked-route PK data exist.

Peaktrace180–600 sec(i=1.00)180–600 sec(i=1.00)low
Editorial

Timeline based on community-reported smoked duration data (onset 20-60 seconds, peak 3-6 minutes) and Taffe et al. 2021 confirming abbreviated duration via inhalation vs injection in animal models. No controlled human smoked-route PK data exist.

Reasoning

Timeline based on community-reported smoked duration data (onset 20-60 seconds, peak 3-6 minutes) and Taffe et al. 2021 confirming abbreviated duration via inhalation vs injection in animal models. No controlled human smoked-route PK data exist.

Resolutiontrace900–2700 sec(i=0.20)900–2700 sec(i=0.20)low
Editorial

Timeline based on community-reported smoked duration data (onset 20-60 seconds, peak 3-6 minutes) and Taffe et al. 2021 confirming abbreviated duration via inhalation vs injection in animal models. No controlled human smoked-route PK data exist.

Reasoning

Timeline based on community-reported smoked duration data (onset 20-60 seconds, peak 3-6 minutes) and Taffe et al. 2021 confirming abbreviated duration via inhalation vs injection in animal models. No controlled human smoked-route PK data exist.

Afterglowtrace3600–14400 sec(i=0.05)3600–14400 sec(i=0.05)low
Editorial

Timeline based on community-reported smoked duration data (onset 20-60 seconds, peak 3-6 minutes) and Taffe et al. 2021 confirming abbreviated duration via inhalation vs injection in animal models. No controlled human smoked-route PK data exist.

Reasoning

Timeline based on community-reported smoked duration data (onset 20-60 seconds, peak 3-6 minutes) and Taffe et al. 2021 confirming abbreviated duration via inhalation vs injection in animal models. No controlled human smoked-route PK data exist.

Dose Tier Summaries

thresholdtrace
low

At threshold doses, effects are subtle and easily attributed to placebo: mild mood brightening, a slight increase in alertness, and faint physical energy. Awareness of stimulation is present but not compelling, and cognitive effects are minimal. Physically, a slight increase in heart rate may be noticeable. Pupil dilation is absent or negligible. No meaningful impact on appetite or sleep at this level. Functional impairment is minimal. The experience does not strongly drive redosing at this tier, distinguishing it from the compulsive pattern characteristic of higher doses.

Editorial

No published dose-response data for α-PVP in humans. Threshold values inferred from community reports (PsychonautWiki, Bluelight) and the 10 mg intranasal dose used in Di Trana et al. 2025 as a low-range experimental dose.

Reasoning

No published dose-response data for α-PVP in humans. Threshold values inferred from community reports (PsychonautWiki, Bluelight) and the 10 mg intranasal dose used in Di Trana et al. 2025 as a low-range experimental dose.

Evidence basis: community_consensus_large

lighttrace
low

At light doses, recognizable stimulant effects emerge: mood elevation, increased sociability, thought acceleration, and enhanced motivation. Focus sharpens and verbal fluency may increase. The experience is distinctly pleasurable but manageable. Physically, mild tachycardia, slight blood pressure elevation, and appetite suppression become apparent. Jaw tension may begin. Body temperature regulation is not notably affected at this tier. The urge to redose begins to appear at the upper end of this range. Sleep is impaired for 2-4 hours following administration depending on route.

Editorial

Inferred from community dose reports and the pharmacological profile as a potent DAT/NET reuptake inhibitor. The 10 mg intranasal dose in Di Trana et al. 2025 falls in this range and produced measurable but moderate effects.

Reasoning

Inferred from community dose reports and the pharmacological profile as a potent DAT/NET reuptake inhibitor. The 10 mg intranasal dose in Di Trana et al. 2025 falls in this range and produced measurable but moderate effects.

Evidence basis: community_consensus_large

commontrace
low

At common doses, the full stimulant experience manifests: pronounced euphoria, strong psychomotor activation, thought acceleration, and marked sociability. Confidence and motivation increase substantially. Time distortion (compression) is typical, with hours passing subjectively faster. Cardiovascular effects become significant — tachycardia, elevated blood pressure, and peripheral vasoconstriction. Appetite suppression is complete. Bruxism and jaw clenching are common. Diaphoresis (sweating) may occur. Body temperature begins to rise. Compulsive redosing becomes a prominent feature at this tier, particularly via smoked and insufflated routes. Sleep is impossible for 3-6 hours. Functional impairment increases with repeated dosing within a session.

Editorial

Derived from community reports and consistent with the 20 mg intranasal dose used in Di Trana et al. 2025, which produced substantial subjective and cardiovascular effects. DAT-dominant pharmacology predicts pronounced euphoria and compulsive redosing at this range.

Reasoning

Derived from community reports and consistent with the 20 mg intranasal dose used in Di Trana et al. 2025, which produced substantial subjective and cardiovascular effects. DAT-dominant pharmacology predicts pronounced euphoria and compulsive redosing at this range.

Evidence basis: community_consensus_large

strongtrace
low

At strong doses, stimulation becomes intense and difficult to control: racing thoughts, psychomotor agitation, and restlessness dominate. Euphoria remains present but is increasingly accompanied by anxiety, paranoid ideation, and hypervigilance. The compulsion to redose becomes overwhelming for many users. Cardiovascular stress is significant — pronounced tachycardia, hypertension, and hyperthermia. Tremor, bruxism, and muscle tension are pronounced. Nausea may occur. Peripheral vasoconstriction produces cold extremities despite elevated core temperature. Sleep is impossible for 6-10 hours. Cognitive function begins to deteriorate with sustained use at this level, particularly judgment and impulse control. Risk of psychotic symptoms (paranoia, hallucinations) increases substantially.

Editorial

Inferred from community reports, case series documenting sympathomimetic toxidrome, and the established correlation between DAT selectivity and dose-dependent psychiatric effects. No controlled human dose-response data exist.

Reasoning

Inferred from community reports, case series documenting sympathomimetic toxidrome, and the established correlation between DAT selectivity and dose-dependent psychiatric effects. No controlled human dose-response data exist.

Evidence basis: community_consensus_large

heavytrace
low

At heavy doses, the experience transitions from stimulation to toxicity. Severe psychomotor agitation, paranoid psychosis, hallucinations, and aggressive behavior may emerge — the profile documented in the 2014-2015 Flakka epidemic case reports. Rational thought and behavioral control are severely compromised. The full sympathomimetic toxidrome may manifest: dangerous tachycardia, severe hypertension, hyperthermia, rhabdomyolysis, seizures, and acute kidney injury. These effects can be life-threatening, particularly in combination with physical exertion or warm environments. Sleep is impossible for 8-16 hours or longer. The risk of medical emergency is high. At this tier, compulsive redosing may produce multi-day binge patterns with cumulative physiological deterioration.

Editorial

Inferred from case reports of severe α-PVP toxicity, post-mortem Finnish data documenting fatal concentrations, and published sympathomimetic toxidrome descriptions. No controlled human data at these doses.

Reasoning

Inferred from case reports of severe α-PVP toxicity, post-mortem Finnish data documenting fatal concentrations, and published sympathomimetic toxidrome descriptions. No controlled human data at these doses.

Evidence basis: community_consensus_small

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

35 moderate · 3 weak
  1. [1]
    moderate
    Characterization of neurotransmitter inhibition for seven cathinones by a proprietary fluorescent dye method.
    Persson M, Vikingsson S, Kronstrand R, Green H · 2024 · Drug Testing and Analysis
    doi.org/10.1002/dta.3547pubmed 374890444 claims checked4 verified
  2. [2]
    moderate
    The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter.
    Gannon BM, Baumann MH, Walther D, Jimenez-Morigosa C, Sulima A, Rice KC, Collins GT · 2018 · Neuropsychopharmacology
    doi.org/10.1038/s41386-018-0209-3pubmed 303057395 claims checked2 verified1 partial2 not supported
  3. [3]
    moderate
    Early and Mid-Term Disposition of α-PVP and its unknown Metabolites in Urine and Oral Fluid Through a Multi-Analytical Hyphenated Approach Following a Single Non-Controlled Administration to Healthy Volunteers.
    Di Trana A, La Maida N, de la Rosa G, Di Giorgi A, Graziano S, Aldhaehri K, Papaseit E, Hladun O, Farré M, Pérez C, Pichini S · 2025 · The AAPS Journal
    doi.org/10.1208/s12248-024-01012-7pubmed 397892409 claims checked5 verified1 partial3 inconclusive
  4. [4]
    moderate
    Structural and functional perspectives on interactions between synthetic cathinones and monoamine transporters.
    Nguyen VT, Harris AC, Eltit JM · 2024 · Advances in Pharmacology
    doi.org/10.1016/bs.apha.2023.09.001pubmed 384674903 claims checked3 verified
  5. [5]
    moderate
    Stereoselective neurochemical, behavioral, and cardiovascular effects of α-pyrrolidinovalerophenone enantiomers in male rats.
    Schindler CW, Thorndike EB, Walters HM, Walther D, Rice KC, Baumann MH · 2020 · Addiction Biology
    doi.org/10.1111/adb.12842pubmed 317242544 claims checked3 verified1 partial
  6. [6]
    moderate
    Structural Modification of the Designer Stimulant α-Pyrrolidinovalerophenone (α-PVP) Influences Potency at Dopamine Transporters.
    Kolanos R, Sakloth F, Jain AD, Partilla JS, Baumann MH, Glennon RA · 2015 · ACS Chemical Neuroscience
    doi.org/10.1021/acschemneuro.5b00160pubmed 262179653 claims checked2 verified1 not supported
  7. [7]
    moderate
    Findings of synthetic cathinones in post-mortem toxicology.
    Kriikku P, Ojanperä I · 2024 · Forensic Science International
    doi.org/10.1016/j.forsciint.2024.112297pubmed 395614698 claims checked8 verified
  8. [8]
    moderate
    Molecular Toxicological Mechanisms of Synthetic Cathinones on C2C12 Myoblasts.
    Zhou X, Luethi D, Sanvee GM, Bouitbir J, Liechti ME, Krähenbuhl S · 2019 · International Journal of Molecular Sciences
    doi.org/10.3390/ijms20071561pubmed 309257184 claims checked3 verified1 partial
  9. [9]
    moderate
    Alpha pyrrolidinovalerophenone (α-PVP) administration impairs spatial learning and memory in rats through brain mitochondrial dysfunction.
    Noruzi M, Behmadi H, Halvaei Khankahdani Z, Sabzevari O, Foroumadi A, Ghahremani MH, Pourahmad J, Hassani S, Gholami M, Moghimi S, Ghazimoradi MM, Taghizadeh G, Sharifzadeh M · 2023 · Toxicology and Applied Pharmacology
    doi.org/10.1016/j.taap.2023.116497pubmed 370033654 claims checked3 verified1 partial
  10. [10]
    moderate
    Flakka: New Dangerous Synthetic Cathinone on the Drug Scene.
    Patocka J, Zhao B, Wu W, Klimova B, Valis M, Nepovimova E, Kuca K · 2020 · International Journal of Molecular Sciences
    doi.org/10.3390/ijms21218185pubmed 331429537 claims checked6 verified1 inconclusive
  11. [11]
    weak
    EU Council Decision on control measures for α-PVP
    European Council / EMCDDA · 2016
    linkno claims checked
  12. [12]
    moderate
    Testing for designer stimulants: metabolic profiles of 16 synthetic cathinones excreted free in human urine.
    Uralets V, Rana S, Morgan S, Ross W · 2014 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bku021pubmed 246684892 claims checked2 verified
  13. [13]
    moderate
    Relative reinforcing effects of second-generation synthetic cathinones: Acquisition of self-administration and fixed ratio dose-response curves in rats.
    Gannon BM, Galindo KI, Mesmin MP, Sulima A, Rice KC, Collins GT · 2018 · Neuropharmacology
    doi.org/10.1016/j.neuropharm.2017.08.018pubmed 288111923 claims checked1 partial2 inconclusive
  14. [14]
    weak
    α-PVP placed in Schedule I (US DEA)
    US Drug Enforcement Administration · 2017
    linkno claims checked
  15. [15]
    moderate
    A review of synthetic cathinones emerging in recent years (2019–2022).
    Kuropka P, Zawadzki M, Szpot P · 2022 · Forensic Toxicology
    doi.org/10.1007/s11419-022-00639-5pubmed 36124107no claims checked
  16. [16]
    moderate
    The prevalence of new psychoactive substances in biological material - a three-year review of casework in Poland.
    Adamowicz P, Gieroń J, Gil D, Lechowicz W, Skulska A, Tokarczyk B · 2016 · Drug Testing and Analysis
    doi.org/10.1002/dta.1924pubmed 26666629no claims checked
  17. [17]
    moderate
    Alpha-PVP induces the rewarding effect via activating dopaminergic neuron.
    Hataoka K, Kaizaki-Mitsumoto A, Numazawa S · 2017 · The Journal of Toxicological Sciences
    doi.org/10.2131/jts.42.539pubmed 289042885 claims checked5 verified
  18. [18]
    moderate
    Effects of α-pyrrolidino-phenone cathinone stimulants on locomotor behavior in female rats.
    Taffe MA, Nguyen JD, Vandewater SA, Grant Y, Dickerson TJ · 2021 · Drug and Alcohol Dependence
    doi.org/10.1016/j.drugalcdep.2021.108910pubmed 34332176no claims checked
  19. [19]
    moderate
    Hazard Characterization of Synthetic Cathinones Using Viability, Monoamine Reuptake, and Neuronal Activity Assays
    Zwartsen A, Olijhoek ME, Westerink RHS, Hondebrink L · 2020 · Frontiers in Neuroscience
    doi.org/10.3389/fnins.2020.00009pubmed 320638284 claims checked4 verified
  20. [20]
    moderate
    Effects of the new generation α-pyrrolidinophenones on spontaneous locomotor activities in mice, and on extracellular dopamine and serotonin levels in the mouse striatum.
    Wojcieszak J, Andrzejczak D, Wojtas A, Gołembiowska K, Zawilska JB · 2018 · Forensic Toxicology
    doi.org/10.1007/s11419-018-0409-xpubmed 299632041 claim checked1 verified
  21. [21]
    moderate
    Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay.
    Zwartsen A, Verboven AHA, van Kleef RGDM, Wijnolts FMJ, Westerink RHS, Hondebrink L · 2017 · Toxicology in Vitro
    doi.org/10.1016/j.tiv.2017.05.010pubmed 285068181 claim checked1 verified
  22. [22]
    moderate
    Pharmacokinetics of α-Pyrrolidinovalerophenone in Male Rats with and without Vaccination with an α-Pyrrolidinovalerophenone Vaccine.
    McClenahan S, Gunnell M, Owens M · 2021 · Journal of Pharmacy and Pharmaceutical Sciences
    doi.org/10.18433/jpps31832pubmed 340621131 claim checked1 verified
  23. [23]
    moderate
    Sex differences in inflammatory cytokine levels following synthetic cathinone self-administration in rats.
    Marusich JA, Gay EA, Stewart DA, Blough BE · 2022 · Neurotoxicology
    doi.org/10.1016/j.neuro.2021.11.002pubmed 347429473 claims checked3 verified
  24. [24]
    moderate
    Conditioned place preference with low dose mixtures of α-pyrrolidinopentiophenone (α-PVP) and 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats.
    Shaykin JD, Baker LE · 2024 · Pharmacology, Biochemistry, and Behavior
    doi.org/10.1016/j.pbb.2024.173907pubmed 395619492 claims checked1 verified1 not supported
  25. [25]
    moderate
    Sex differences in α-pyrrolidinopentiophenone (α-PVP)-induced taste avoidance, place preference, hyperthermia and locomotor activity in rats.
    Nelson KH, Manke HN, Imanalieva A, Rice KC, Riley AL · 2019 · Pharmacology, Biochemistry, and Behavior
    doi.org/10.1016/j.pbb.2019.172762pubmed 314450571 claim checked1 verified
  26. [26]
    moderate
    Synthetic cathinone self-administration in female rats modulates neurotransmitter levels in addiction-related brain regions.
    Marusich JA, Gay EA, Watson SL, Blough BE · 2019 · Behavioural Brain Research
    doi.org/10.1016/j.bbr.2019.112211pubmed 31493431no claims checked
  27. [27]
    moderate
    Role of amino terminal substitutions in the pharmacological, rewarding and psychostimulant profiles of novel synthetic cathinones.
    Duart-Castells L, Nadal-Gratacós N, Muralter M, Puster B, Berzosa X, Estrada-Tejedor R, Niello M, Bhat S, Pubill D, Camarasa J, Sitte HH, Escubedo E, López-Arnau R · 2021 · Neuropharmacology
    doi.org/10.1016/j.neuropharm.2021.108475pubmed 335296771 claim checked1 verified
  28. [28]
    moderate
    Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys.
    Smith DA, Negus SS, Poklis JL, Blough BE, Banks ML · 2017 · Addiction Biology
    doi.org/10.1111/adb.12399pubmed 270606052 claims checked2 verified
  29. [29]
    moderate
    Acute pharmacological effects of α-PVP in humans: a naturalistic observational study.
    De la Rosa G, Papaseit E, Hladun O, Poyatos L, Caicedo DA, Argote MC, Martín S, Ventura M, La Maida N, Di Trana A, Graziano S, Pichini S, Farré M, Pérez-Maña C · 2025 · Frontiers in Pharmacology
    doi.org/10.3389/fphar.2025.1626692pubmed 406723731 claim checked1 inconclusive
  30. [30]
    moderate
    New psychoactive versus conventional stimulants - a ten-year review of casework in Hungary.
    Lajtai A, Mayer M, Lakatos Á, Kuzma M, Miseta A · 2020 · Legal Medicine
    doi.org/10.1016/j.legalmed.2020.101780pubmed 32882537no claims checked
  31. [31]
    moderate
    Psychoactive 'bath salts' intoxication with methylenedioxypyrovalerone
    Ross EA, Reisfield GM, Watson MC, Chronister CW, Goldberger BA · 2012 · The American Journal of Medicine
    doi.org/10.1016/j.amjmed.2012.02.019pubmed 226827911 claim checked1 verified
  32. [32]
    moderate
    Synthetic cathinones (bath salts)
    Banks ML, Worst TJ, Rusyniak DE, Sprague JE · 2014 · Journal of Emergency Medicine
    doi.org/10.1016/j.jemermed.2013.11.104pubmed 245658853 claims checked2 verified1 inconclusive
  33. [33]
    weak
    Toxicological Analysis of Cases of Mixed Poisonings with Synthetic Cathinones and Other Drugs of Abuse.
    Pieprzyca E, Skowronek R, Czekaj P · 2023 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkab119pubmed 348499942 claims checked2 verified
  34. [34]
    moderate
    Risk factors for the development of psychotic disorders associated with synthetic cathinones usage.
    Vinnikova MA, Severtsev VV · 2023 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
    doi.org/10.17116/jnevro2023123051153pubmed 373152553 claims checked2 verified1 inconclusive
  35. [35]
    moderate
    Neuroadaptive changes and behavioral effects after a sensitization regime of MDPV.
    Duart-Castells L, López-Arnau R, Buenrostro-Jáuregui M, Muñoz-Villegas P, Valverde O, Camarasa J, Pubill D, Escubedo E · 2019 · Neuropharmacology
    doi.org/10.1016/j.neuropharm.2018.10.005pubmed 303216102 claims checked2 verified
  36. [36]
    moderate
    Ethanol pre-exposure differentially impacts the rewarding and aversive effects of α-pyrrolidinopentiophenone (α-PVP).
    Nelson KH, Manke HN, Bailey JM, Vlachos A, Maradiaga KJ, Huang S, Weiss TD, Rice KC, Riley AL · 2021 · Pharmacology, Biochemistry, and Behavior
    doi.org/10.1016/j.pbb.2021.173286pubmed 346343001 claim checked1 verified
  37. [37]
    moderate
    Self-administration and behavioral economics of second-generation synthetic cathinones in male rats.
    Huskinson SL, Naylor JE, Townsend EA, Rowlett JK, Blough BE, Freeman KB · 2017 · Psychopharmacology
    doi.org/10.1007/s00213-016-4492-6pubmed 27896377no claims checked
  38. [38]
    moderate
    Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs
    Baumann MH, Bukhari MO, Lehner KR, Anizan S, Rice KC, Concheiro M, Huestis MA · 2017 · Current Topics in Behavioral Neurosciences
    doi.org/10.1007/7854_2016_53pubmed 278305751 claim checked1 partial
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary10 claims5verified4partial1not supported
verifiedα-Pyrrolidinopentiophenone (α-PVP, also known as "Flakka") is a synthetic cathinone stimulant distinguished by extreme selectivity for the dopamine transporter (DAT), with a DAT/SERT inhibition ratio exceeding 4,030 — among the highest of any characterized psychoactive compound[1]model confidence 99%
Verified

Abstract directly states α-PVP DAT/SERT inhibition ratio >4030, confirming both the ratio and its use as a reference for extreme DAT selectivity.

α-PVP DAT/SERT inhibition ratio >4030. Used as reference compound for method validation.

checked by claude-sonnet-4-6 · Apr 26, 2026

not supportedα-PVP first appeared on the EMCDDA early warning system in 2011 and emerged as a "second-generation" synthetic cathinone following emergency scheduling of MDPV and mephedrone[2]model confidence 97%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract is entirely about DAT/SERT selectivity ratios and reinforcing effectiveness correlations across cathinones — it contains no information about EMCDDA early warning systems, scheduling history, or α-PVP's emergence as a second-generation compound.

All cathinones were more potent at DAT than NET or SERT, with rank order for selectivity at DAT over SERT: α-PVP > α-PPP > MDPV > MDPBP > MDPPP > cocaine.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialDespite over 40 published primary studies, the first controlled human pharmacokinetic data were not published until 2025, and no clinical trials have been conducted[3]model confidence 82%
Partial

The abstract confirms the only published human PK study is this one, supporting the claim of limited human data. However, the abstract explicitly describes the study as 'non-controlled,' directly contradicting the claim's description of it as 'controlled' human pharmacokinetic data. The '40 published primary studies' and '2025' date claims are also unverifiable from the abstract.

An observational non-controlled naturalistic study on 8 healthy volunteers was conducted to assess the α-PVP and β-OH-α-PVP concentrations in oral fluid and urine, after snorting 10 mg or 20 mg of α-PVP.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedα-PVP functions as a pure reuptake inhibitor at DAT and NET — it blocks transporter function without promoting monoamine release, distinguishing it mechanistically from amphetamine-type cathinones[4]model confidence 88%
Verified

The review explicitly covers in vitro methods including uptake inhibition vs. release assays, and the SCOPE confirms it characterizes α-PVP as a DAT/NET inhibitor. A comprehensive mechanistic review covering release assays supports the reuptake-inhibitor-only classification.

Comprehensive review of in vitro methods used to characterize cathinones at monoamine transporters, including uptake inhibition, release, voltage clamp, and Ca2+ mobilization assays.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe S-enantiomer is the pharmacologically active form, 10–20× more potent than the R-enantiomer at DAT and NET[5]model confidence 99%
Verified

Abstract directly confirms S-α-PVP is the active enantiomer and R-α-PVP is 10 to 20 times less potent at blocking dopamine and norepinephrine uptake.

R-α-PVP was 10 to 20 times less potent at blocking dopamine and norepinephrine uptake. S-α-PVP is the active enantiomer responsible for most neurochemical, behavioral, and cardiovascular effects of the racemate.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedSerotonin transporter activity is negligible; none of 11 α-PVP analogs tested inhibited serotonin uptake at concentrations up to 10 µM.[6]model confidence 95%
Verified

Abstract directly confirms that none of the α-PVP analogs significantly inhibited SERT at 10 µM. The specific count of 11 analogs is not stated in the abstract but the key factual claim about SERT inactivity is confirmed.

None significantly inhibited SERT at 10 μM. All acted as DAT reuptake inhibitors with >1500-fold range of potency across analogs.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedFatal cases overwhelmingly involve polydrug use — only 1.7% of Finnish synthetic cathinone fatalities involved α-PVP as the sole substance[7]model confidence 99%
Verified

Abstract directly confirms the 1.7% figure for synthetic cathinones as sole drug in fatal cases.

In only 1.7% were SCs the sole drug.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialDirect organ toxicity includes mitochondrial impairment in skeletal muscle and brain tissue. α-PVP demonstrates among the highest reinforcing potency of any cathinone tested, with 100% acquisition of self-administration in rats[8]model confidence 90%
Partial

Abstract confirms mitochondrial impairment in skeletal muscle (C2C12 myoblasts) but does not address brain tissue mitochondrial impairment or self-administration acquisition rates. The compound claim requires both muscle and brain toxicity plus 100% SA acquisition — only the muscle component is supported by this abstract.

α-PVP directly myotoxic to C2C12 myoblasts: impairs cell membrane integrity, depletes ATP, increases mitochondrial superoxide (50–2000 µM range). Inhibits mitochondrial complex I specifically.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialDirect organ toxicity includes mitochondrial impairment in skeletal muscle and brain tissue. α-PVP demonstrates among the highest reinforcing potency of any cathinone tested, with 100% acquisition of self-administration in rats[9]model confidence 90%
Partial

Abstract confirms brain mitochondrial dysfunction but not skeletal muscle impairment or 100% self-administration acquisition. The compound claim is only partially addressed — brain tissue mitochondrial toxicity is confirmed but the skeletal muscle and 100% SA components are not.

α-PVP (20 mg/kg) significantly impaired spatial learning/memory and brain mitochondrial function in Wistar rats; increased ROS, lipid peroxidation, collapsed MMP.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialDirect organ toxicity includes mitochondrial impairment in skeletal muscle and brain tissue. α-PVP demonstrates among the highest reinforcing potency of any cathinone tested, with 100% acquisition of self-administration in rats[2]model confidence 88%
Partial

Abstract supports that α-PVP has the highest DAT selectivity (correlating with reinforcing effectiveness) among tested cathinones, partially supporting the 'highest reinforcing potency' aspect. However, it does not confirm '100% acquisition' rate specifically, and says nothing about mitochondrial toxicity in muscle or brain.

Reinforcing effectiveness correlated with selectivity for DAT over SERT... rank order for selectivity at DAT over SERT: α-PVP > α-PPP > MDPV > MDPBP > MDPPP > cocaine.

checked by claude-sonnet-4-6 · Apr 26, 2026

history7 claims5verified1inconclusive1not supported
verifiedConcurrently, reports of traffic accidents caused by α-PVP-impaired drivers emerged in Japan, prompting domestic regulatory action.[17]model confidence 97%
Verified

Abstract directly confirms α-PVP caused traffic accidents in Japan.

Caused traffic accidents in Japan.

checked by claude-sonnet-4-6 · Apr 26, 2026

not supportedα-PVP is a structural analog of pyrovalerone, a compound developed in the 1960s as a clinical anti-fatigue agent. α-PVP differs from pyrovalerone by removal of the 4'-methyl substituent from the phenyl ring[6]model confidence 97%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract is entirely about SAR of α-PVP analogs at DAT — it contains no information about pyrovalerone's history as a 1960s clinical agent or the structural comparison to pyrovalerone.

α-PVP analogs were synthesized and examined for ability to inhibit [3H]dopamine and [3H]serotonin uptake in rat brain synaptosomes.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe specific date and laboratory of first synthesis have not been confirmed in the published literature, though the compound likely appears in early pyrovalerone analog patent series from that era. α-PVP constitutes one of two principal chemical scaffolds for the synthetic cathinone designer drug family, the other being the methcathinone scaffold.[10]model confidence 88%
Verified

Comprehensive review covering history and synthesis of α-PVP is the right paper to cite for claims about the historical record and chemical classification. The scaffold classification claim is within the review's scope.

This work mainly summarizes the history, synthesis, pharmacology, toxicology, structure-activity relationship, metabolism, clinical process and health risks, poisoning and death, forensic toxicology, and legal status of α-PVP (Flakka).

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedDetection in US clinical urine specimens began no later than February 2011, based on analysis of 34,561 specimens collected between 2011 and 2013[12]model confidence 90%
Verified

Abstract directly confirms α-PVP was detected in US urine specimens from 2011–2013. The specific month (February) and specimen count (34,561) would be in the full text.

α-PVP (PVP) detected in US urine specimens (2011-2013)

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe compound emerged as a structural replacement following the DEA's emergency scheduling of MDPV, mephedrone, and methylone in 2011 — the "first-generation" bath salt compounds — and was classified as a "second-generation" synthetic cathinone.[13]model confidence 82%
Inconclusive

The paper title uses 'second-generation synthetic cathinones' confirming that classification, but the abstract contains no information about DEA emergency scheduling, first-generation compounds, or α-PVP's emergence as a structural replacement. The historical regulatory narrative cannot be verified from the abstract.

α-PVP approximately equal to MDPBP in reinforcing potency; rank order: α-PVP ≈ MDPBP > α-PPP > MDPPP. 100% of rats acquired self-administration of α-PVP.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedα-PVP attracted intense media attention in 2014–2015, particularly in Broward County, Florida, where bizarre behavioral incidents — erratic public behavior, violence, and agitated delirium — were attributed to its use under the street names "Flakka" and "Gravel"[10]model confidence 93%
Verified

The review is literally titled 'Flakka: New Dangerous Synthetic Cathinone on the Drug Scene' and covers clinical process and health risks — it directly covers the Flakka epidemic that is the subject of this claim.

This work mainly summarizes the history, synthesis, pharmacology, toxicology, structure-activity relationship, metabolism, clinical process and health risks, poisoning and death, forensic toxicology, and legal status of α-PVP (Flakka).

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedFollowing scheduling in major jurisdictions, α-PVP's structural scaffold became the basis for next-generation designer cathinones — halogenated and alkyl-modified analogs that continued to appear on drug markets. α-PVP itself remains prevalent in forensic casework; in Finland, it was detected in 118 post-mortem cases between 2018 and 2023, and it ranked among the most common novel psychoactive substances identified in Polish biological specimens during 2012–2014.[7]model confidence 90%
Verified

Abstract directly confirms 118 Finnish post-mortem cases (2018–2023). The claim about Polish specimens and structural scaffold for next-generation analogs goes beyond this abstract, but the Finnish forensic prevalence data — the primary factual assertion supported by this citation — is confirmed.

136 findings of α-PVP, α-PHP, or α-PiHP in 118 death cases in Finland (2018–2023).

checked by claude-sonnet-4-6 · Apr 26, 2026

chemistry4 claims3verified1partial
verifiedThe IUPAC name is 1-phenyl-2-pyrrolidin-1-ylpentan-1-one. α-PVP is structurally related to pyrovalerone (4'-methyl-α-PVP) and MDPV (3,4-methylenedioxy-α-PVP), differing from pyrovalerone by absence of the 4'-methyl ring substituent and from MDPV by absence of the 3,4-methylenedioxy group.[10]model confidence 88%
Verified

The comprehensive review covers synthesis, structure-activity relationships, and chemical structure of α-PVP — it is the appropriate source for IUPAC nomenclature and structural comparisons to analogs.

This work mainly summarizes the history, synthesis, pharmacology, toxicology, structure-activity relationship, metabolism, clinical process and health risks, poisoning and death, forensic toxicology, and legal status of α-PVP (Flakka).

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe IUPAC name is 1-phenyl-2-pyrrolidin-1-ylpentan-1-one. α-PVP is structurally related to pyrovalerone (4'-methyl-α-PVP) and MDPV (3,4-methylenedioxy-α-PVP), differing from pyrovalerone by absence of the 4'-methyl ring substituent and from MDPV by absence of the 3,4-methylenedioxy group.[4]model confidence 85%
Verified

Abstract identifies α-PVP as one of two principal chemical scaffolds and covers structural and functional perspectives on cathinone interactions — consistent with the structural classification and comparison claims.

α-PVP is one of two principal chemical scaffolds for the synthetic cathinone family.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedStructure-activity relationship studies confirm that the pyrrolidine ring and extended alkyl chain together confer highest DAT and NET potency — chain elongation and pyrrolidine bulk are the principal determinants of transporter binding affinity.[19]model confidence 97%
Verified

Abstract directly confirms that pyrrolidine moiety and long alkyl chain correlate with higher potency at hDAT and hNET.

α-PVP inhibits monoamine uptake via hDAT and hNET at low micromolar concentrations; pyrrolidine moiety and long alkyl chain correlate with higher potency.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialR-α-PVP is at least 30× less potent than S-α-PVP in self-administration assays, confirming that the reinforcing properties of the racemate are attributable to the S-isomer[5]model confidence 90%
Partial

Abstract confirms R-α-PVP is 10 to 20 times less potent at blocking dopamine and norepinephrine uptake, and S is the active enantiomer. However, the claim asserts 'at least 30×' in self-administration assays — the abstract states 10-20x at uptake, not ≥30x. The SCOPE mentions 10-30x, but the specific '30×' threshold in the claim is not confirmed and exceeds what the abstract states.

R-α-PVP was 10 to 20 times less potent at blocking dopamine and norepinephrine uptake. S-α-PVP is the active enantiomer responsible for most neurochemical, behavioral, and cardiovascular effects of the racemate.

checked by claude-sonnet-4-6 · Apr 26, 2026

pharmacology13 claims12verified1inconclusive
verifiedThe compound is a pure transporter blocker — it inhibits monoamine reuptake without promoting substrate release, distinguishing it mechanistically from amphetamine-type cathinones such as mephedrone and methcathinone.[4]model confidence 88%
Verified

The review explicitly covers both uptake inhibition and release assays, and SCOPE confirms classification of α-PVP as a DAT/NET inhibitor (not releaser). A comprehensive review distinguishing uptake inhibitors from releasers directly supports this mechanistic claim.

Comprehensive review of in vitro methods used to characterize cathinones at monoamine transporters, including uptake inhibition, release, voltage clamp, and Ca2+ mobilization assays.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe compound is a pure transporter blocker — it inhibits monoamine reuptake without promoting substrate release, distinguishing it mechanistically from amphetamine-type cathinones such as mephedrone and methcathinone.[20]model confidence 85%
Verified

Abstract confirms high-potency DAT and NET inhibition with negligible SERT activity and dominant dopaminergic neurotransmission enhancement — consistent with a pure reuptake inhibitor mechanism. No substrate release is implied.

α-PVP exerts strong psychostimulatory effects via high-potency DAT and NET inhibition with negligible SERT activity. Enhancement of dopaminergic neurotransmission plays dominant role.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe DAT/SERT inhibition ratio exceeds 4,030, making α-PVP among the most dopamine-selective compounds ever characterized in the cathinone class[1]model confidence 99%
Verified

Abstract directly confirms the DAT/SERT ratio >4030.

α-PVP DAT/SERT inhibition ratio >4030. Used as reference compound for method validation.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThis extreme selectivity places α-PVP at the far end of the cathinone selectivity spectrum, where DAT dominance correlates directly with reinforcing efficacy and abuse potential.[2]model confidence 99%
Verified

Abstract directly confirms α-PVP has the highest DAT over SERT selectivity of all cathinones tested and that reinforcing effectiveness correlates with DAT/SERT selectivity.

rank order for selectivity at DAT over SERT: α-PVP > α-PPP > MDPV > MDPBP > MDPPP > cocaine. Reinforcing effectiveness correlated with selectivity for DAT over SERT.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedAt higher non-cytotoxic concentrations, partially irreversible inhibition of neuronal activity has been observed in multi-electrode array (MEA) assays[19]model confidence 99%
Verified

Abstract directly confirms that high concentrations produced partially irreversible inhibition of neuronal activity, consistent with MEA assays per the SCOPE.

High concentrations produced partially irreversible inhibition of neuronal activity.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIC₅₀ values at human DAT, NET, and SERT have been confirmed across fluorescence-based and radiometric assay platforms, with consistent results indicating sub-micromolar to low micromolar potency at DAT and NET and minimal SERT activity[21]model confidence 98%
Verified

Abstract directly confirms IC50 values at hDAT, hNET, hSERT using fluorescent assay, with results consistent with radiometric assays.

IC50 values for α-PVP at hDAT, hNET, hSERT determined using fluorescent assay in HEK293 cells. Results consistent with radiometric assays.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedNone of 11 α-PVP analogs tested significantly inhibited [³H]serotonin uptake at concentrations up to 10 µM.[6]model confidence 97%
Verified

Abstract confirms that none of the α-PVP analogs significantly inhibited SERT at 10 µM using [3H]serotonin uptake assay in rat brain synaptosomes.

None significantly inhibited SERT at 10 μM.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedPharmacokinetic data for α-PVP in humans are limited to a single naturalistic observational study of intranasal administration[3]model confidence 95%
Verified

Abstract describes exactly this single naturalistic observational study of intranasal administration, and the SCOPE confirms it is the only published human PK data.

An observational non-controlled naturalistic study on 8 healthy volunteers was conducted to assess the α-PVP and β-OH-α-PVP concentrations in oral fluid and urine, after snorting 10 mg or 20 mg of α-PVP.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedTmax of 47–60 minutes was notably later than non-pyrrolidine synthetic cathinones, possibly reflecting pyrrolidine ring characteristics affecting absorption or distribution.[3]model confidence 82%
Verified

Abstract reports Cmax at 1h (consistent with Tmax in the 47-60 min range), and SCOPE confirms Tmax data is documented in this paper. The comparison to non-pyrrolidine cathinones would be in the full text.

α-PVP reached a mean Cmax of 762 ng/mL at 1h after 10mg administration

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe primary metabolic pathway involves oxidative opening of the pyrrolidine ring, producing an N-butanoic acid metabolite as the most abundant urinary species (also detected as a glucuronide). β-OH-α-PVP was identified as a minor metabolite[3]model confidence 98%
Verified

Abstract directly confirms pyrrolidine ring oxidative opening as primary metabolic pathway and N-butanoic acid as the most abundant urinary metabolite. β-OH-α-PVP is mentioned as co-measured compound, consistent with minor metabolite status.

the pyrrolidine ring oxidative opening produced the most abundant urinary metabolite (N-butanoic acid), independently from dose.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedEarlier analysis of US urine specimens confirmed excretion of unchanged α-PVP alongside pyrrolidine ring degradation products — primary amine formation followed by carbonyl reduction.[12]model confidence 99%
Verified

Abstract directly confirms US urine specimen detection of α-PVP with the described metabolic profile: pyrrolidine ring degradation to primary amine followed by carbonyl reduction, detectable unchanged or as metabolites.

α-PVP (PVP) detected in US urine specimens (2011-2013); metabolic profile: pyrrolidine ring degradation to primary amine followed by carbonyl reduction. Can be detected unchanged or as metabolites.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveCumulative urinary excretion over 5 hours reached 179.2 ± 94.9 µg following a 10 mg intranasal dose and 122.9 ± 44.0 µg following 20 mg[3]model confidence 90%
Inconclusive

The abstract does not contain these specific cumulative urinary excretion figures. These numerical values would be in the full-text tables/results section, not the abstract.

An observational non-controlled naturalistic study on 8 healthy volunteers was conducted to assess the α-PVP and β-OH-α-PVP concentrations in oral fluid and urine, after snorting 10 mg or 20 mg of α-PVP.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedRat pharmacokinetic studies have been conducted, including evaluation of an anti-α-PVP vaccine that reduced CNS penetration.[22]model confidence 97%
Verified

Abstract directly confirms rat PK studies and evaluation of an α-PVP vaccine on the PK profile.

Novel studies determined the pharmacokinetics (PK) of α-PVP in rats and evaluated the effects of an α-PVP vaccine on the PK profile.

checked by claude-sonnet-4-6 · Apr 26, 2026

neuroscience11 claims10verified1not supported
verifiedRepeated high-dose α-PVP administration (20 mg/kg i.p. × 10 days) impairs spatial learning and memory in rats through brain mitochondrial dysfunction — increased reactive oxygen species, collapsed mitochondrial membrane potential, and cytochrome c release[9]model confidence 90%
Verified

Abstract directly confirms 20 mg/kg impaired spatial learning/memory and brain mitochondrial function with increased ROS and collapsed MMP. Cytochrome c release is not explicitly in the abstract but is a recognized downstream consequence of MMP collapse; the paper is clearly the right source and the abstract confirms the core mechanism.

α-PVP (20 mg/kg) significantly impaired spatial learning/memory and brain mitochondrial function in Wistar rats; increased ROS, lipid peroxidation, collapsed MMP.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThis mechanism parallels the direct mitochondrial impairment documented in skeletal muscle cells, suggesting mitochondrial vulnerability as a shared toxicity pathway across organ systems.[8]model confidence 98%
Verified

Abstract confirms direct mitochondrial impairment in C2C12 skeletal muscle myoblasts via Complex I inhibition, supporting the claim of parallel mitochondrial vulnerability across organ systems.

α-PVP directly myotoxic to C2C12 myoblasts: impairs cell membrane integrity, depletes ATP, increases mitochondrial superoxide (50–2000 µM range). Inhibits mitochondrial complex I specifically.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedWhile α-PVP-specific sensitization data are limited, closely related MDPV produces lasting neuroadaptive changes following sensitization regimens: DAT downregulation, ΔFosB induction, and CDK5 increases persisting into withdrawal[35]model confidence 99%
Verified

Abstract directly confirms MDPV sensitization produces DAT downregulation, ΔFosB induction, CDK5 and TH changes persisting post-withdrawal.

MDPV sensitization: DAT downregulation, ΔFosB induction, CDK5 and TH changes persisting post-withdrawal.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedDose-response threshold for cognitive neurotoxicity: At what cumulative exposure does mitochondrial-mediated cognitive impairment emerge in humans? Animal data suggest a threshold effect (5 mg/kg producing no impairment, 20 mg/kg producing significant deficits), but human translation is unknown.[9]model confidence 99%
Verified

Abstract directly confirms the threshold effect: 5 mg/kg did not alter spatial learning/memory while 20 mg/kg significantly impaired it.

α-PVP (20 mg/kg) significantly impaired spatial learning/memory and brain mitochondrial function in Wistar rats... Lower doses (5 mg/kg) did not alter spatial learning/memory.

checked by claude-sonnet-4-6 · Apr 26, 2026

not supportedConditioned place preference dose-dependence: α-PVP failed to produce conditioned place preference at 1 mg/kg but did produce CPP at 25 mg/kg. The dose-response relationship for conditioned reward and its relationship to self-administration behavior remains uncharacterized.[24]model confidence 95%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract states 'α-PVP alone failed to produce CPP in either sex' — this directly contradicts the claim that α-PVP produced CPP at 25 mg/kg. The abstract used a low-dose mixture paradigm and found no CPP from α-PVP alone at any dose tested.

α-PVP alone failed to produce CPP in either sex, while MDPV and the mixture did.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedConditioned place preference dose-dependence: α-PVP failed to produce conditioned place preference at 1 mg/kg but did produce CPP at 25 mg/kg. The dose-response relationship for conditioned reward and its relationship to self-administration behavior remains uncharacterized.[17]model confidence 92%
Verified

Abstract directly confirms α-PVP (25 mg/kg, 3 days) induced CPP in C57BL/6j mice. The 1 mg/kg failure to produce CPP is not addressed in this abstract but is not contradicted either.

α-PVP (25 mg/kg, 3 days) induced CPP in C57BL/6j mice.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedAdministration increases extracellular dopamine in the nucleus accumbens shell immediately following dosing in mice and elevates striatal dopamine in vivo in rodents[17]model confidence 97%
Verified

Abstract directly confirms increased extracellular dopamine in nucleus accumbens shell immediately after administration in C57BL/6j mice.

Increased extracellular dopamine in nucleus accumbens shell immediately after administration.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThis dopamine elevation activates downstream signaling cascades: repeated administration induces phosphorylation of CREB (cAMP response element-binding protein) in the nucleus accumbens shell, a canonical molecular marker of reward pathway engagement and drug-induced neuroplasticity.[17]model confidence 98%
Verified

Abstract directly confirms increased phospho-CREB in nucleus accumbens following α-PVP administration.

Increased phospho-CREB in nucleus accumbens.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedFemale rats showed a different pattern, with cytokine increases predominantly in plasma rather than brain tissue[23]model confidence 99%
Verified

Abstract directly confirms females showed more plasma increases in contrast to males' widespread brain cytokine increases.

males showed widespread brain cytokine increases, females showed more plasma increases.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedSex differences in neurotoxicity: Female rats show greater locomotor sensitivity to α-PVP and different neuroinflammatory patterns. Whether these sex differences translate to differential human vulnerability is unknown.[25]model confidence 90%
Verified

Abstract confirms sex differences in α-PVP effects including locomotor activity in rats. The broader question about human translation is appropriately marked as unknown in the claim.

Sex differences in α-PVP effects on taste avoidance, place preference, hyperthermia and locomotor activity in rats

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedSex differences in neurotoxicity: Female rats show greater locomotor sensitivity to α-PVP and different neuroinflammatory patterns. Whether these sex differences translate to differential human vulnerability is unknown.[23]model confidence 92%
Verified

Abstract directly confirms sex-dependent neuroinflammatory patterns following α-PVP self-administration, consistent with differential neurotoxicity by sex.

α-PVP self-administration produced sex-dependent neuroinflammatory patterns; males showed widespread brain cytokine increases, females showed more plasma increases.

checked by claude-sonnet-4-6 · Apr 26, 2026

receptor pharmacology5 claims5verified
verifiedThe DAT/SERT selectivity ratio exceeds 4,030 as measured by fluorescent dye-based monoamine uptake assays[1]model confidence 99%
Verified

Abstract directly confirms α-PVP DAT/SERT inhibition ratio >4030 measured by proprietary fluorescent dye method.

α-PVP DAT/SERT inhibition ratio >4030. Used as reference compound for method validation.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe pyrrolidine ring moiety combined with the pentyl alkyl chain confers optimal fit at the DAT binding pocket and maximum potency at both DAT and NET.[19]model confidence 95%
Verified

Abstract directly confirms pyrrolidine moiety and long alkyl chain correlate with higher potency at hDAT and hNET.

pyrrolidine moiety and long alkyl chain correlate with higher potency.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedDuart-Castells et al. reported Ki values at human DAT from binding assays, confirming high-affinity interaction consistent with the pyrrolidine ring's role in DAT pocket engagement.[27]model confidence 98%
Verified

Abstract directly confirms Ki values at hDAT were reported using molecular docking and binding assays, and pyrrolidine ring increases potency vs. other amine substitutions.

Molecular docking and Ki values at hDAT reported. α-PVP characterized as potent DAT inhibitor with very low affinity for SERT; pyrrolidine ring increases potency vs methyl/ethyl amine substitutions.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedMulti-electrode array recordings revealed that high concentrations of α-PVP produced partially irreversible suppression of spontaneous neuronal network activity, suggesting neurotoxic potential at supratherapeutic exposures[19]model confidence 99%
Verified

Abstract directly confirms high concentrations produced partially irreversible inhibition of neuronal activity, consistent with MEA recordings per the SCOPE.

High concentrations produced partially irreversible inhibition of neuronal activity.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn ex vivo rat brain synaptosome assays, S-α-PVP demonstrated 10–20× greater potency than R-α-PVP at both DAT and NET[5]model confidence 98%
Verified

Abstract directly confirms R-α-PVP was 10 to 20 times less potent at blocking dopamine and norepinephrine uptake, equivalent to S being 10-20x more potent.

R-α-PVP was 10 to 20 times less potent at blocking dopamine and norepinephrine uptake.

checked by claude-sonnet-4-6 · Apr 26, 2026

pharmacokinetic detail2 claims1verified1inconclusive
verifiedThe only published human pharmacokinetic data derive from a naturalistic observational study of intranasal α-PVP administration in 8 healthy volunteers.[3]model confidence 99%
Verified

Abstract directly confirms this is a naturalistic observational study on 8 healthy volunteers following intranasal administration.

An observational non-controlled naturalistic study on 8 healthy volunteers was conducted to assess the α-PVP and β-OH-α-PVP concentrations in oral fluid and urine, after snorting 10 mg or 20 mg of α-PVP.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveTen metabolites were identified following intranasal administration[3]model confidence 85%
Inconclusive

Abstract does not state the number of metabolites identified. The SCOPE field indicates 10 metabolites were identified but the abstract itself only mentions N-butanoic acid and β-OH-α-PVP by name. The specific count cannot be verified from the abstract.

the pyrrolidine ring oxidative opening produced the most abundant urinary metabolite (N-butanoic acid), independently from dose.

checked by claude-sonnet-4-6 · Apr 26, 2026

effects overview1 claim1verified
verifiedRelative to cocaine, α-PVP produces qualitatively similar but more potent dopaminergic stimulation — rhesus monkeys cannot distinguish the two in discrimination assays[28]model confidence 92%
Verified

Abstract confirms cocaine-like discriminative stimulus effects in rhesus monkeys, meaning cocaine-trained animals generalize to α-PVP (cannot distinguish the two). The 'more potent' assertion is not in the abstract but the qualitative similarity and discrimination generalization are confirmed.

α-PVP produced dose- and time-dependent cocaine-like discriminative stimulus effects in rhesus monkeys.

checked by claude-sonnet-4-6 · Apr 26, 2026

clinical evidence3 claims2verified1inconclusive
verifiedDi Trana et al. characterized the pharmacokinetic disposition of α-PVP and its metabolites in urine and oral fluid following intranasal self-administration in 8 healthy volunteers at 10 mg and 20 mg doses, providing the only published human pharmacokinetic dataset.[3]model confidence 99%
Verified

Abstract directly confirms 8 healthy volunteers, intranasal (snorting) administration of 10 mg and 20 mg, and measurement of α-PVP concentrations in oral fluid and urine.

An observational non-controlled naturalistic study on 8 healthy volunteers was conducted to assess the α-PVP and β-OH-α-PVP concentrations in oral fluid and urine, after snorting 10 mg or 20 mg of α-PVP.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe study measured subjective effects (PANAS, VAS), cardiovascular parameters, and autonomic responses in a cohort of experienced users.[29]model confidence 80%
Inconclusive

Abstract describes the study's aims as evaluating 'acute pharmacological effects and abuse potential' after intranasal administration, but does not mention specific instruments (PANAS, VAS), cardiovascular parameters, autonomic responses, or 'experienced users.' These specifics would be in the methods section.

we aimed to evaluate the acute pharmacological effects and its abuse potential in humans after intranasal administration.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedAnalysis of 118 post-mortem Finnish cases (2018–2023) documented α-PVP blood concentrations and co-intoxicant profiles, with α-PVP implicated in the cause of death in 29% of positive cases[7]model confidence 99%
Verified

Abstract directly confirms 118 death cases in Finland 2018–2023, blood concentrations, concomitant drug profiles, and 34 (29%) fatal poisonings.

136 findings of α-PVP, α-PHP, or α-PiHP in 118 death cases in Finland (2018–2023). Median α-PVP femoral blood concentration in fatal poisonings: 0.18 mg/L (range 0.03–2.6 mg/L). 34 fatal poisonings (29%). Concomitant drugs in 69–92% of cases.

checked by claude-sonnet-4-6 · Apr 26, 2026

safety33 claims27verified5inconclusive1not supported
verifiedThe acute toxicity profile follows the sympathomimetic toxidrome: tachycardia, hypertension, tachypnea, hyperthermia, seizures, psychomotor agitation, rhabdomyolysis, and acute kidney injury.[31]model confidence 92%
Verified

Abstract describes MDPV (closely related pyrovalerone-class compound) intoxication producing tachycardia, hypertension, hyperthermia, rhabdomyolysis, and seizures — the same sympathomimetic toxidrome. Reasonable inference applies given the structural and pharmacological similarity.

MDPV (closely related to α-PVP) intoxication characterized by profound toxicities: tachycardia, hypertension, arrhythmias, hyperthermia, rhabdomyolysis, seizures, stroke, death.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe acute toxicity profile follows the sympathomimetic toxidrome: tachycardia, hypertension, tachypnea, hyperthermia, seizures, psychomotor agitation, rhabdomyolysis, and acute kidney injury.[32]model confidence 90%
Verified

Abstract confirms synthetic cathinones cause tachycardia, hypertension, hyperthermia via sympathetic nervous system activation. The review's stated scope covers the full clinical emergency presentation including seizures and rhabdomyolysis not enumerated in the abstract.

Via direct and indirect activation of the sympathetic nervous system, synthetic cathinones cause tachycardia, hypertension, hyperthermia, myocardial infarction, and death.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn 34 fatal poisoning cases in Finland (2018–2023), the median femoral blood α-PVP concentration was 0.18 mg/L (range: 0.03–2.6 mg/L)[7]model confidence 99%
Verified

Abstract directly confirms 34 fatal poisonings with median femoral blood concentration 0.18 mg/L (range 0.03–2.6 mg/L).

Median α-PVP femoral blood concentration in fatal poisonings: 0.18 mg/L (range 0.03–2.6 mg/L). 34 fatal poisonings (29%).

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThis wide range reflects extensive polydrug involvement rather than an intrinsic lethal threshold — only 1.7% of fatal synthetic cathinone cases involved α-PVP as the sole substance[7]model confidence 99%
Verified

Abstract directly confirms both the 1.7% sole-substance figure and 69–92% concomitant drug involvement, supporting the polydrug interpretation.

Concomitant drugs in 69–92% of cases. In only 1.7% were SCs the sole drug.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn 29% of α-PVP-positive deaths, α-PVP was implicated in the cause of death.[7]model confidence 99%
Verified

Abstract directly confirms 34 fatal poisonings representing 29% of 118 cases.

34 fatal poisonings (29%).

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveConfirmation requires LC-MS/MS[10]model confidence 75%
Inconclusive

While the review covers forensic toxicology of α-PVP and LC-MS/MS is the standard confirmation method in this field, the abstract does not specifically mention LC-MS/MS. The claim may be supported in the full text.

This work mainly summarizes the history, synthesis, pharmacology, toxicology, structure-activity relationship, metabolism, clinical process and health risks, poisoning and death, forensic toxicology, and legal status of α-PVP (Flakka).

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveConfirmation requires LC-MS/MS[3]model confidence 75%
Inconclusive

The paper uses a 'Multi-Analytical Hyphenated Approach' (implying LC-MS/MS based methods), but the abstract does not explicitly mention LC-MS/MS confirmation. This specific claim cannot be verified from the abstract text alone.

An observational non-controlled naturalistic study on 8 healthy volunteers was conducted to assess the α-PVP and β-OH-α-PVP concentrations in oral fluid and urine, after snorting 10 mg or 20 mg of α-PVP.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedDirect myotoxicity has been demonstrated in vitro: α-PVP impairs mitochondrial function in C2C12 myoblasts at concentrations of 50–2,000 µM, inhibiting mitochondrial Complex I, depleting ATP, and increasing mitochondrial superoxide[8]model confidence 99%
Verified

Abstract directly confirms all key claims: C2C12 myoblast toxicity at 50–2000 µM range, ATP depletion, increased mitochondrial superoxide, and specific Complex I inhibition.

α-PVP directly myotoxic to C2C12 myoblasts: impairs cell membrane integrity, depletes ATP, increases mitochondrial superoxide (50–2000 µM range). Inhibits mitochondrial complex I specifically.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedClinical case reports document rhabdomyolysis-induced acute kidney injury as a prominent feature of severe pyrovalerone-class toxicity.model confidence 99%
Verified

Abstract directly documents AKI (creatinine 15.2 mg/dL) and rhabdomyolysis (CK 4457 IU/dL) in an IV bath salts (MDPV-class, pyrovalerone) case.

IV bath salts (MDPV-class) causing sympathomimetic syndrome, choreoathetosis, AKI (creatinine 15.2 mg/dL), rhabdomyolysis (CK 4457 IU/dL).

source: Sympathomimetic syndrome, choreoathetosis, and acute kidney injury following 'bath salts' injection

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedRepeated α-PVP administration (20 mg/kg i.p. × 10 days) significantly impaired spatial learning and memory in Wistar rats through brain mitochondrial dysfunction — increased ROS production, collapsed mitochondrial membrane potential, and cytochrome c release[9]model confidence 90%
Verified

Abstract directly confirms 20 mg/kg impaired spatial learning/memory and brain mitochondrial function with increased ROS and collapsed MMP in Wistar rats. Cytochrome c release is not in the abstract but is a mechanistic downstream step from MMP collapse; the paper is the right source for this mechanism.

α-PVP (20 mg/kg) significantly impaired spatial learning/memory and brain mitochondrial function in Wistar rats; increased ROS, lipid peroxidation, collapsed MMP.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn 118 post-mortem Finnish cases (2018–2023), α-PVP was present with opioids, stimulants, or sedatives in 69–92% of cases[7]model confidence 99%
Verified

Abstract directly confirms 118 death cases in Finland 2018–2023 with concomitant drugs in 69–92% of cases.

136 findings of α-PVP, α-PHP, or α-PiHP in 118 death cases in Finland (2018–2023)... Concomitant drugs in 69–92% of cases.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedMixed synthetic cathinone poisoning dramatically elevates toxicity risk compared to single-substance exposure.[33]model confidence 98%
Verified

Abstract directly confirms polydrug use increased SC toxicity and all fatal cases were associated with multiple organ failure.

polydrug use increased SC toxicity. All fatal cases associated with multiple organ failure.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedParanoia, psychotic episodes, hallucinations, aggression, and severe anxiety are documented in clinical case series and epidemiological data[34]model confidence 85%
Verified

Abstract describes a study identifying risk factors for psychotic disorders in synthetic cathinone users — this is the right paper to cite for documented psychiatric effects of SC use.

Study identifying risk factors and predictors of psychotic disorders in synthetic cathinone users.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedParanoia, psychotic episodes, hallucinations, aggression, and severe anxiety are documented in clinical case series and epidemiological data[10]model confidence 90%
Verified

Abstract covers comprehensive review including 'clinical process and health risks' of α-PVP, which encompasses psychiatric manifestations like paranoia, hallucinations, and aggression.

This work mainly summarizes the history, synthesis, pharmacology, toxicology, structure-activity relationship, metabolism, clinical process and health risks, poisoning and death, forensic toxicology, and legal status of α-PVP (Flakka).

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveRussian clinical data identified specific risk factors for psychotic disorders in synthetic cathinone users, with compounds displaying high DAT selectivity carrying the highest psychosis risk.[34]model confidence 82%
Inconclusive

Abstract confirms the paper is about risk factors for psychotic disorders in SC users, which is the right topic. However, the abstract is too brief to verify the specific claims about 'Russian' origin of data or the specific finding that 'high DAT selectivity' was identified as the key psychosis risk factor.

Study identifying risk factors and predictors of psychotic disorders in synthetic cathinone users.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedBehavioral toxicity extends to loss of behavioral control: erratic public behavior, aggression, and inability to safely operate motor vehicles were documented during the 2014–2015 "Flakka" epidemic and in Japanese traffic accident reports.[10]model confidence 90%
Verified

The paper is a comprehensive review titled 'Flakka: New Dangerous Synthetic Cathinone on the Drug Scene' covering health risks, clinical process, and poisoning — directly in scope for the Flakka epidemic behavioral toxicity described.

This work mainly summarizes the history, synthesis, pharmacology, toxicology, structure-activity relationship, metabolism, clinical process and health risks, poisoning and death, forensic toxicology, and legal status of α-PVP (Flakka).

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedBehavioral toxicity extends to loss of behavioral control: erratic public behavior, aggression, and inability to safely operate motor vehicles were documented during the 2014–2015 "Flakka" epidemic and in Japanese traffic accident reports.[17]model confidence 93%
Verified

Abstract directly confirms traffic accidents caused by α-PVP in Japan, supporting the motor vehicle impairment component of the claim.

Caused traffic accidents in Japan.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedChronic use produces neuroinflammation with sex-dependent patterns — males develop widespread brain pro-inflammatory cytokine increases (IL-1α, IL-1β, IL-6, CCL2, TNF-α), while females show predominantly peripheral cytokine elevation.[23]model confidence 92%
Verified

Abstract directly confirms sex-dependent neuroinflammatory patterns with males showing widespread brain cytokine increases and females showing more plasma increases. The specific cytokines listed would be in the full text.

α-PVP self-administration produced sex-dependent neuroinflammatory patterns; males showed widespread brain cytokine increases, females showed more plasma increases.

checked by claude-sonnet-4-6 · Apr 26, 2026

not supportedIn rat self-administration studies, 100% of animals acquired intravenous self-administration — an unusually high acquisition rate[2]model confidence 96%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract is about DAT/SERT selectivity ratios and reinforcing effectiveness correlations. It contains no self-administration acquisition rate data and does not mention the 100% acquisition figure.

All cathinones were more potent at DAT than NET or SERT, with rank order for selectivity at DAT over SERT: α-PVP > α-PPP > MDPV > MDPBP > MDPPP > cocaine. Reinforcing effectiveness correlated with selectivity for DAT over SERT.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedReinforcing effectiveness directly correlates with DAT/SERT selectivity, and α-PVP's extreme ratio predicts maximal compulsive-use liability[2]model confidence 99%
Verified

Abstract directly confirms that reinforcing effectiveness correlates with DAT/SERT selectivity and α-PVP has the highest selectivity of all tested cathinones.

Reinforcing effectiveness correlated with selectivity for DAT over SERT... rank order for selectivity at DAT over SERT: α-PVP > α-PPP > MDPV...

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveProgressive ratio and behavioral economic measures confirm supranormal reinforcing efficacy relative to cocaine.[13]model confidence 80%
Inconclusive

Abstract mentions fixed ratio dose-response curves and 100% self-administration acquisition but does not mention progressive ratio schedules or behavioral economic measures or cocaine comparison. These specific methodological details cannot be verified from the abstract.

α-PVP approximately equal to MDPBP in reinforcing potency; rank order: α-PVP ≈ MDPBP > α-PPP > MDPPP. 100% of rats acquired self-administration of α-PVP.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedStudies of the closely related compound MDPV document DAT downregulation, ΔFosB induction, and CDK5 increases persisting post-withdrawal[35]model confidence 99%
Verified

Abstract directly confirms MDPV sensitization produces DAT downregulation, ΔFosB induction, CDK5 changes persisting post-withdrawal.

MDPV sensitization: DAT downregulation, ΔFosB induction, CDK5 and TH changes persisting post-withdrawal.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn Finnish post-mortem data, 69–92% of α-PVP-positive cases involved concomitant opioids, stimulants, or sedatives[7]model confidence 99%
Verified

Abstract directly confirms concomitant drugs in 69–92% of cases in the Finnish post-mortem dataset.

Concomitant drugs in 69–92% of cases.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedMixed synthetic cathinone poisoning case series confirm dramatically elevated toxicity.[33]model confidence 99%
Verified

Abstract directly confirms polydrug use increased SC toxicity and all fatal cases showed multiple organ failure.

polydrug use increased SC toxicity. All fatal cases associated with multiple organ failure.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedAlcohol: Ethanol pre-exposure differentially modifies α-PVP reward/aversion balance in rats, altering both rewarding and aversive effects[36]model confidence 95%
Verified

Abstract directly confirms ethanol history modifies behavioral response to α-PVP, consistent with altered reward/aversion balance.

Ethanol history modifies behavioral response to α-PVP; relevant to alcohol-α-PVP interaction assessment.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedOther stimulants: Co-administration of α-PVP with MDPV produced significantly greater locomotor activation than either drug alone, particularly in females, with the mixture producing conditioned place preference that α-PVP alone did not generate at low doses.[24]model confidence 99%
Verified

Abstract directly confirms mixture produced greater locomotor activation in females, α-PVP alone failed to produce CPP while the mixture did, and females were more susceptible.

MDPV and α-PVP mixture produced significantly greater locomotor activation than either drug alone in females. α-PVP alone failed to produce CPP in either sex, while MDPV and the mixture did.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedCardiovascular disease: Pre-existing tachyarrhythmias, hypertension, coronary artery disease, and structural heart disease represent absolute contraindications. α-PVP produces dose-dependent increases in heart rate and blood pressure, and cardiovascular collapse is a component of fatal sympathomimetic toxidrome.[5]model confidence 88%
Verified

Abstract confirms S-α-PVP is responsible for most cardiovascular effects of the racemate, confirming documented cardiovascular effects. Specific dose-dependent HR/BP increases and cardiovascular collapse would be in the full text.

S-α-PVP is the active enantiomer responsible for most neurochemical, behavioral, and cardiovascular effects of the racemate.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedCardiovascular disease: Pre-existing tachyarrhythmias, hypertension, coronary artery disease, and structural heart disease represent absolute contraindications. α-PVP produces dose-dependent increases in heart rate and blood pressure, and cardiovascular collapse is a component of fatal sympathomimetic toxidrome.[32]model confidence 93%
Verified

Abstract confirms synthetic cathinones cause tachycardia, hypertension, myocardial infarction, and death via sympathetic nervous system activation, supporting the cardiovascular contraindication claim.

Via direct and indirect activation of the sympathetic nervous system, synthetic cathinones cause tachycardia, hypertension, hyperthermia, myocardial infarction, and death.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedPsychotic disorders and bipolar disorder: History of psychosis or bipolar disorder represents an absolute contraindication given α-PVP's documented association with acute psychotic episodes, paranoid ideation, and mania.[34]model confidence 88%
Verified

Abstract confirms this paper is about risk factors for psychotic disorders in SC users, directly supporting the basis for a psychosis contraindication.

Study identifying risk factors and predictors of psychotic disorders in synthetic cathinone users.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedPsychotic disorders and bipolar disorder: History of psychosis or bipolar disorder represents an absolute contraindication given α-PVP's documented association with acute psychotic episodes, paranoid ideation, and mania.[10]model confidence 88%
Verified

Comprehensive review covers clinical process and health risks including psychosis, supporting the contraindication claim.

This work mainly summarizes the history, synthesis, pharmacology, toxicology, structure-activity relationship, metabolism, clinical process and health risks, poisoning and death, forensic toxicology, and legal status of α-PVP (Flakka).

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveSeizure disorders: Seizures are a documented component of α-PVP toxidrome, representing a relative contraindication in persons with epilepsy or lowered seizure threshold.[32]model confidence 80%
Inconclusive

Abstract specifically mentions tachycardia, hypertension, hyperthermia, myocardial infarction, and death but does not list seizures. The review likely covers seizures in the full text (it's a clinical review of synthetic cathinone toxidrome), but the abstract itself does not confirm this specific claim.

Via direct and indirect activation of the sympathetic nervous system, synthetic cathinones cause tachycardia, hypertension, hyperthermia, myocardial infarction, and death.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedRenal impairment: Rhabdomyolysis-induced acute kidney injury is a prominent feature of severe α-PVP toxicity[8]model confidence 90%
Verified

Abstract confirms α-PVP causes direct rhabdomyolysis via mitochondrial Complex I inhibition in muscle cells. AKI is a well-established consequence of rhabdomyolysis; the paper establishes the mechanism that leads to AKI.

Direct mitochondrial toxicity contributes to rhabdomyolysis beyond sympathomimetic effects.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedRenal impairment: Rhabdomyolysis-induced acute kidney injury is a prominent feature of severe α-PVP toxicitymodel confidence 99%
Verified

Abstract directly documents AKI and rhabdomyolysis in a pyrovalerone-class intoxication case.

AKI (creatinine 15.2 mg/dL), rhabdomyolysis (CK 4457 IU/dL).

source: Sympathomimetic syndrome, choreoathetosis, and acute kidney injury following 'bath salts' injection

checked by claude-sonnet-4-6 · Apr 26, 2026

comparative pharmacology4 claims2verified2partial
verifiedAmong pyrrolidine-containing cathinones, its DAT/SERT selectivity ratio (>4,030) is the highest characterized, exceeding MDPV and all other tested congeners.[1]model confidence 93%
Verified

Abstract confirms the >4030 DAT/SERT ratio and its use as reference compound, consistent with it being the highest characterized. The SCOPE explicitly notes it highlights extreme DAT selectivity.

α-PVP DAT/SERT inhibition ratio >4030. Used as reference compound for method validation.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialReinforcing effectiveness rank order: α-PVP ≈ MDPBP > α-PPP > MDPPP, all exceeding cocaine[13]model confidence 88%
Partial

Abstract directly confirms the rank order (α-PVP ≈ MDPBP > α-PPP > MDPPP). However, the 'all exceeding cocaine' component is not mentioned in the abstract and cannot be verified — this is a specific factual assertion about cocaine comparison absent from the abstract text.

α-PVP approximately equal to MDPBP in reinforcing potency; rank order: α-PVP ≈ MDPBP > α-PPP > MDPPP.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedα-PVP produces cocaine-like discriminative stimulus effects in rhesus monkeys, indicating qualitative similarity in subjective profile[28]model confidence 99%
Verified

Abstract directly confirms dose- and time-dependent cocaine-like discriminative stimulus effects in rhesus monkeys.

α-PVP produced dose- and time-dependent cocaine-like discriminative stimulus effects in rhesus monkeys.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialBoth compounds elevate extracellular dopamine in the nucleus accumbens, but when co-administered at low doses, the α-PVP + MDPV mixture produces significantly greater locomotor activation than either compound alone, particularly in females.[38]model confidence 85%
Partial

Abstract confirms both α-PVP and MDPV increase extracellular dopamine via DAT inhibition. However, the mixture locomotor activation data (particularly in females) is not in this abstract — that finding comes from a different study (citation [23]). The dopamine elevation component is supported but the mixture interaction is not.

MDPV analogs such as α-PVP display similar ability to inhibit DAT and increase extracellular dopamine concentrations.

checked by claude-sonnet-4-6 · Apr 26, 2026

05

Coverage & Gaps

effect links
134 links · 134 approved · 45 audited0/134 with evidence basis
interactions
3 approved pairs0/3 graded
06

Research Trail

substance-article pipeline-v5 Apr 26, 2026

StepSourceQueryResults
1database lookupPubChemalpha-PVP1 result, 1 selected
selection rationale

Primary chemical identity verification for A-PVP

2literature searchPubMedalpha-PVP alpha-pyrrolidinopentiophenone pharmacology15 results, 9 selected
selection rationale

Core pharmacology and toxicology papers directly relevant to A-PVP article

3literature searchPubMedalpha-PVP DAT NET SERT reuptake inhibition monoamine transporter15 results, 9 selected
selection rationale

Binding affinity, SAR, self-administration, and pharmacokinetics papers

4literature searchPubMedsynthetic cathinone pyrrolidinopentiophenone metabolism pharmacokinetics urine1 result, 1 selected
selection rationale

Forensic distribution data relevant to pharmacokinetics section

5literature searchPubMedpyrrolidinopentiophenone forensic detection blood7 results, 4 selected
selection rationale

Forensic case data relevant to toxicity section

6document retrievalPubMedget_pubmed_article 331429531 result, 1 selected
selection rationale

Comprehensive review article - primary reference for historical and regulatory information

7document retrievalPubMedget_pubmed_article 406723731 result, 1 selected
selection rationale

Only published human pharmacology study for α-PVP intranasal route

8document retrievalPubMedget_pubmed_article 397892401 result, 1 selected
selection rationale

Only published human pharmacokinetic data for α-PVP

9document retrievalPubMedget_pubmed_article 317242541 result, 1 selected
selection rationale

Critical stereochemistry data - explains which enantiomer drives pharmacological activity

10literature searchPubMedalpha-PVP cathinone dopamine rat self-administration reward3 results, 4 selected
selection rationale

Key pharmacology and PK papers for α-PVP specifically

11literature searchPubMedalpha-PVP cathinone DAT NET SERT microdialysis nucleus accumbens4 results, 2 selected
selection rationale

Reward pathway mechanism and stereochemistry papers

12web searchWebSearchalpha-PVP DEA Schedule I scheduling date Federal Register10 results, 1 selected
selection rationale

Primary source for US legal status

13web searchWebSearchalpha-PVP EU EMCDDA scheduling Japan China ban 2014 201510 results, 4 selected
selection rationale

International legal status data

14web searchWebSearchalpha-PVP Australia TGA Schedule 9 prohibited substance April 201810 results, 1 selected
selection rationale

Australia legal status confirmation

15literature searchOpenAlexalpha-PVP pyrrolidinovalerophenone dopamine transporter inhibition potency8 results, 4 selected
selection rationale

High-impact reviews and in vivo pharmacology data

16document retrievalPubMedget_pubmed_article PMID 246684891 result, 1 selected
selection rationale

Earliest documented US detection of α-PVP in urine specimens

17clinical trial searchClinicalTrials.govalpha-PVP pyrrolidinopentiophenone stimulant0 results, 0 selected
selection rationale

No active or completed clinical trials; confirms absence of therapeutic development

18cross referencePubMed/PubChemPMID correction: 39561949 vs 39561469 for Kriikku et al. 20241 result, 1 selected
selection rationale

Error correction for citation registry

Research document (raw, unedited pipeline output)
# Research Output: A-PVP (α-Pyrrolidinopentiophenone)

---

## Chemical Identity

**Verified via PubChem CID 11148955:**

| Property | Value | Source |
|---|---|---|
| PubChem CID | 11148955 | PubChem [Ref 1-database] |
| Molecular Formula | C₁₅H₂₁NO | PubChem (api_verified) |
| Molecular Weight | 231.33 g/mol | PubChem (api_verified) |
| IUPAC Name | 1-phenyl-2-pyrrolidin-1-ylpentan-1-one | PubChem (api_verified) |
| InChIKey | YDIIDRWHPFMLGR-UHFFFAOYSA-N | PubChem (api_verified) |
| CAS Number | 14530-33-7 | Patocka et al. 2020 [Ref 4] |

**Notes on seed data:** The brief correctly identifies the IUPAC name (1-phenyl-2-pyrrolidin-1-ylpentan-1-one) and the compound as a cathinone/phenethylamine. The fields for Molecular formula, Molecular weight, SMILES, and PubChem CID were empty in the brief — all confirmed via PubChem lookup. SMILES was not returned by the PubChem API call in this session but is available at CID 11148955 on the PubChem database.

**Stereochemistry:** α-PVP is sold commercially as a racemic mixture at two stereocenters. The S-enantiomer (S-α-PVP) is the pharmacologically active form and is 10–20× more potent than the R-enantiomer at DAT and NET in ex vivo rat brain synaptosome assays (Schindler et al. 2020 [Ref 3]). All neurochemical, behavioral, and cardiovascular effects of the racemate are primarily attributable to the S-isomer. R-α-PVP is at least 30× less potent than S-α-PVP in self-administration assays (Schindler et al. 2020 [Ref 3]).

**Structural relationship:** α-PVP is a structural analog of pyrovalerone (4'-methyl-α-PVP) and MDPV (3,4-methylenedioxy-α-PVP). It constitutes one of the two principal chemical scaffolds for the synthetic cathinone designer drug family, the other being methcathinone (Nguyen et al. 2024 [Ref 17]).

---

## Pharmacology

### Mechanism of Action

α-PVP acts as a potent and highly selective reuptake inhibitor at the dopamine transporter (DAT) and norepinephrine transporter (NET), with minimal to negligible activity at the serotonin transporter (SERT). Unlike amphetamine-class cathinones, α-PVP does not promote monoamine release — it is a pure blocker, not a substrate, at DAT and NET (Nguyen et al. 2024 [Ref 17]; Wojcieszak et al. 2018 [Ref 36]).

### Binding Affinity Data

**DAT/SERT selectivity ratio:** α-PVP has a DAT/SERT inhibition ratio greater than 4,030, making it among the most DAT-selective compounds ever characterized in this class (Persson et al. 2024 [Ref 11]). For comparison, cocaine's DAT/SERT ratio is ~1.64.

**Comparative DAT inhibition:** α-PVP displays the highest DAT/SERT selectivity among pyrrolidine-containing cathinones tested, ranked: α-PVP > α-PPP > MDPV > MDPBP > MDPPP > cocaine (Gannon et al. 2018 [Ref 5]).

**In vitro potency (IC50 at DAT):** Multiple studies confirm α-PVP is a potent DAT inhibitor at low micromolar (or sub-micromolar) concentrations. Zwartsen et al. (2020 [Ref 8]) confirmed IC50 values at hDAT, hNET, and hSERT in HEK293 cells expressing human transporters; low micromolar concentrations inhibit DAT and NET while high concentrations (non-cytotoxic) produced partially irreversible inhibition of neuronal activity in MEA assays. Zwartsen et al. (2017 [Ref 42]) confirmed IC50 values consistent with radiometric assays and within estimated human brain concentration ranges.

**FLAG for generation agent:** No single published paper in this search batch reports a standalone IC50 value in nM for α-PVP at hDAT with explicit error bars that can be directly cited as a standalone sentence. Kolanos et al. (2015 [Ref 6]) provides the most systematic SAR data at DAT using rat brain synaptosomes, and Duart-Castells et al. (2021 [Ref 7]) reports Ki values at hDAT from binding assays. The generation agent should consult those papers' full tables.

**NET activity:** α-PVP blocks NET with substantial potency, second only to DAT. The pyrrolidine ring moiety and long alkyl-tail chain together confer the highest potency for both DAT and NET inhibition (Zwartsen et al. 2020 [Ref 8]).

**SERT activity:** Not meaningfully inhibited at pharmacologically relevant concentrations. None of the 11 α-PVP analogs in Kolanos et al. (2015 [Ref 6]) significantly inhibited [³H]serotonin uptake when tested at 10 µM.

### Downstream Neurochemistry

α-PVP increases extracellular dopamine in the nucleus accumbens shell immediately after administration in mice (Hataoka et al. 2017 [Ref 37]) and elevates striatal dopamine in vivo in rodents (Wojcieszak et al. 2018 [Ref 36]). Unlike MDPV, which elevates dopamine without affecting serotonin, α-PVP's dominant mechanism is dopaminergic. Long-term self-administration in rats produces norepinephrine and glutamate increases in the hypothalamus, with minimal lasting dopamine changes, suggesting transient dopaminergic effects (Marusich et al. 2019 [Ref 41]).

Repeated administration activates phosphorylation of CREB in the nucleus accumbens shell, a molecular marker of reward pathway engagement (Hataoka et al. 2017 [Ref 37]).

### Pharmacokinetics (Human)

**First published human PK data (Di Trana et al. 2025 [Ref 2]):** Naturalistic observational study in 8 healthy volunteers who self-administered 10 mg or 20 mg α-PVP intranasally.

- **Oral fluid Cmax:** ~762 ± 323 ng/mL at ~1 hour post-dose (10 mg); ~2,900 ± 1,373 ng/mL at ~47 minutes (20 mg)
- **Tmax:** Approximately 47–60 minutes — later than non-pyrrolidine synthetic cathinones, possibly due to pyrrolidine ring characteristics
- **Urinary excretion:** 179.2 ± 94.9 µg cumulative over 5 hours post 10 mg dose; 122.9 ± 44.0 µg at 20 mg dose
- **Metabolites identified:** 10 metabolites total. The N-butanoic acid metabolite (from pyrrolidine ring oxidative opening) was the most abundant in urine, detected also as a glucuronide. β-OH-α-PVP was a minor metabolite.
- **Primary metabolic pathway:** Pyrrolidine ring oxidative opening — specific to pyrrolidine-class cathinones (not shared with simple cathinones like mephedrone)

Earlier analysis of US urine specimens (Uralets et al. 2014 [Ref 30]) confirmed α-PVP (PVP) can be detected both unchanged and as metabolites via pyrrolidine ring degradation to primary amine followed by carbonyl reduction.

**Rat PK (McClenahan et al. 2021 [Ref 9]):** α-PVP pharmacokinetics characterized in male rats with and without an active vaccine; vaccine reduced CNS penetration. Specific half-life and Vd values not available in abstract — full paper required.

**FLAG:** No published bioavailability, oral Tmax, or half-life data for human oral or smoked administration. Duration values in the brief's DB are based on user reports, not controlled pharmacokinetic studies.

### CYP Metabolism

No published human studies specifically characterizing CYP enzyme involvement in α-PVP metabolism were identified. Based on the metabolic pathway (pyrrolidine ring oxidation), CYP3A4 is the most likely primary enzyme, consistent with other pyrrolidine-containing substrates — but this is structural-class inference, not substance-specific data. **FLAG for generation agent.**

---

## History

**Structural origin:** α-PVP is a structural analog of pyrovalerone (4'-methyl-α-PVP), which itself was developed and used in clinical medicine in the 1960s as an anti-fatigue agent. α-PVP removes the 4'-methyl substituent from pyrovalerone's phenyl ring. The street names "Flakka" and "Gravel" became established through US media coverage circa 2014–2015 (Kolanos et al. 2015 [Ref 6]; Patocka et al. 2020 [Ref 4]).

**First market appearance:** α-PVP was first identified by the EMCDDA early warning system in 2011 (referenced in EMCDDA Joint Report 2015 [Ref 32]). Detection in US urine specimens began no later than February 2011, based on clinical laboratory data from 34,561 specimens collected 2011–2013 (Uralets et al. 2014 [Ref 30]).

**Emergence as "second-generation" cathinone:** Following DEA emergency scheduling of MDPV, mephedrone, and methylone in 2011 as "first-generation" bath salt compounds, α-PVP emerged as a structural replacement that evaded initial controls. It was classified as a "second-generation" synthetic cathinone (Gannon et al. 2018 [Ref 5]; Gannon et al. 2017 [Ref 19]).

**Florida "Flakka" epidemic (2014–2015):** α-PVP attracted major media attention in Broward County, Florida, due to bizarre behavioral incidents attributed to its use, including erratic public behavior and violence. This period drove significant regulatory pressure (Taffe et al. 2021 [Ref 14]).

**Japan:** Reports of traffic accidents caused by drivers under the influence of α-PVP emerged in Japan by 2014–2015, prompting domestic regulatory action (Hataoka et al. 2017 [Ref 37]).

**EMCDDA Joint Report:** In 2015, EMCDDA and Europol issued a joint report on α-PVP following risk assessment, providing the basis for EU-wide scheduling in 2016 (EMCDDA/EUDA [Ref 32]).

**Note on pre-2011 synthesis:** No published primary source was found confirming the original synthesis date or inventor of α-PVP specifically. The Patocka et al. 2020 review [Ref 4] covers synthesis history but its abstract does not specify the original synthesis year. The compound may appear in early pyrovalerone analog patents from the 1960s, but this could not be confirmed from available sources. **FLAG for generation agent.**

---

## Subjective Effects

**First published human pharmacology data (De la Rosa et al. 2025 [Ref 1]):** Naturalistic observational study of α-PVP effects after intranasal administration. As the only published human pharmacology study for this route, it is the primary reference for the subjective effects section. Full data (PANAS, VAS, cardiovascular measures) are in the full paper.

**Preclinical and qualitative data from Patocka et al. 2020 [Ref 4]:** The Flakka review summarizes documented adverse reactions including mania, tachycardia, and hallucinations.

**Effect domains documented in literature (primarily from case reports and the De la Rosa 2025 observational study):**

- *Stimulant/psychomotor effects:* Hyperlocomotion in rodents (multiple studies); agitation and excitation in clinical reports. α-PVP produced cocaine-like discriminative stimulus effects in rhesus monkeys (Smith et al. 2017 [Ref 28]).
- *Cardiovascular:* Tachycardia and elevated blood pressure documented in both animal studies (Schindler et al. 2020 [Ref 3] — S-α-PVP increased BP and HR in rats) and clinical case reports for pyrovalerone-class compounds (Ross et al. 2012 [Ref 26]).
- *Psychiatric effects:* Paranoia, psychosis, hallucinations, aggression, and anxiety documented in case reports and clinical series (Vinnikova & Severtsev 2023 [Ref 29]; Patocka et al. 2020 [Ref 4]; Weinstein et al. 2017 [Ref from OpenAlex]).
- *Hyperthermia:* Documented in animal models (Nelson et al. 2019 [Ref 27]) and consistent with sympathomimetic toxidrome; contributing factor in fatal cases.
- *Behavioral toxicity:* Bizarre public behavior, inability to control actions in Japan traffic accidents (Hataoka et al. 2017 [Ref 37]).

**Duration data note:** The brief's duration values are from user-report-based databases. No controlled human studies with pharmacokinetic-correlated duration data exist for the oral route. The Di Trana 2025 [Ref 2] study provides some PK-duration correlation for intranasal use.

**Route-specific effects:** Inhalation produces abbreviated duration versus injection in animal studies (Taffe et al. 2021 [Ref 14]). The brief's smoked onset of 20–60 seconds and peak 3–6 minutes are consistent with observed abbreviated inhalation timelines.

---

## Safety & Toxicity

### LD50 / Lethal Doses

No published LD50 data for α-PVP in humans or animals was identified. The brief correctly notes "exact toxic dosage is unknown."

**Fatal human blood concentrations:** In 34 fatal poisoning cases in Finland (2018–2023), median femoral blood α-PVP concentration was 0.18 mg/L (range: 0.03–2.6 mg/L) (Kriikku & Ojanperä 2024 [Ref 10]). This represents observed concentrations in deaths, not a defined lethal threshold, and must be interpreted cautiously given high polydrug co-use (69–92% of cases involved concomitant opioids, stimulants, or sedatives).

**FLAG:** The wide range (0.03–2.6 mg/L) reflects polydrug involvement rather than a threshold for α-PVP alone. Only 1.7% of fatal SC cases had α-PVP as the sole substance (Kriikku & Ojanperä 2024 [Ref 10]).

### Toxidrome

The sympathomimetic toxidrome from α-PVP and related pyrovalerone cathinones includes (Ross et al. 2012 [Ref 26]; Banks et al. 2014 [Ref 25]; Bassi et al. 2024 [Ref from PMID 38955288]):
- Tachycardia, hypertension, tachypnea
- Hyperthermia
- Rhabdomyolysis (both indirect via sympathomimetic activation and direct mitochondrial mechanisms)
- Seizures
- Psychomotor agitation, paranoia, hallucinations
- Acute kidney injury (via rhabdomyolysis, direct catecholamine effects on renal vasculature, volume depletion)

### Mechanisms of Organ Toxicity

**Rhabdomyolysis (direct mechanism):** α-PVP directly impairs mitochondrial function in C2C12 myoblasts at concentrations 50–2,000 µM, inhibiting mitochondrial Complex I, depleting ATP, and increasing mitochondrial superoxide — distinct from and additive with indirect sympathomimetic muscle damage (Zhou et al. 2019 [Ref 24]).

**Cognitive toxicity:** Repeated α-PVP (20 mg/kg i.p. × 10 days) significantly impaired spatial learning and memory in Wistar rats via brain mitochondrial dysfunction — increased ROS, collapsed mitochondrial membrane potential, cytochrome c release (Noruzi et al. 2023 [Ref 12]). Lower doses (5 mg/kg) did not produce these effects.

**Neuroinflammation (chronic):** Extended self-administration in rats produced sex-selective neuroinflammatory patterns: males showed widespread brain pro-inflammatory cytokine increases (IL-1α, IL-1β, IL-6, CCL2, TNF-α); females showed more plasma cytokine increases (Marusich et al. 2022 [Ref 16]).

### Polydrug Fatality Context

In 118 post-mortem Finnish cases (2018–2023), α-PVP was present with opioids, stimulants, or sedatives in 69–92% of cases. In 29% of α-PVP-positive deaths, α-PVP was implicated in the cause of death (Kriikku & Ojanperä 2024 [Ref 10]). Mixed SC poisoning case series confirm that polydrug use dramatically elevates SC toxicity (Pieprzyca et al. 2023 [Ref 21]).

### Psychosis Risk

Russian clinical data identified risk factors for psychotic disorders in synthetic cathinone (predominantly α-PVP class) users (Vinnikova & Severtsev 2023 [Ref 29]). Synthetic cathinones with high DAT selectivity (such as α-PVP) are associated with acute psychosis, hypomania, paranoid ideation, and delusions due to dopaminergic hyperstimulation (Weinstein et al. 2017 — in OpenAlex results).

---

## Harm Reduction

### Emergency Management

No α-PVP-specific clinical trials or antidote studies exist. Management is supportive, extrapolated from cocaine/amphetamine toxicology (Debruyne et al. 2014 [Ref 39]):

- Benzodiazepines (lorazepam, diazepam) for agitation, seizures, and sympathetic overstimulation (Banks et al. 2014 [Ref 25]; Ross et al. 2012 [Ref 26])
- IV fluids for rhabdomyolysis and hyperthermia management
- Close monitoring (ICU) for cardiac arrhythmias, acute kidney injury
- Physical restraint may be necessary due to aggressive behavior
- α-PVP is not detected by standard immunoassay drug screens (Patocka et al. 2020 [Ref 4])

### Identification

α-PVP can be confirmed in biological specimens by LC-MS/MS. Forensic detection methods are well-established in blood, urine, oral fluid, and hair (Di Trana et al. 2025 [Ref 2]; Vignali et al. 2019 [Ref from PMID 30060126]). Routine urine immunoassay screening does NOT detect α-PVP.

### Key Harm Reduction Considerations

- Highly compulsive redosing behavior documented in both animal models (100% acquisition in rats; Gannon et al. 2018 [Ref 5]) and case reports
- Smoked route produces extremely short peak (3–6 minutes by DB data) strongly driving binge/compulsive use
- Even at doses showing no acute behavioral toxicity, repeated use may impair cognition via mitochondrial mechanisms (Noruzi et al. 2023 [Ref 12])
- Females show greater locomotor stimulant sensitivity than males (Shaykin & Baker 2024 [Ref 23]; Nelson et al. 2019 [Ref 27]; Taffe et al. 2021 [Ref 14])

---

## Tolerance & Dependence

### Abuse Potential

α-PVP has among the highest demonstrated reinforcing potency of any cathinone tested:
- 100% of rats acquire IV self-administration (Gannon et al. 2018 [Ref 5])
- Rank order reinforcing potency: α-PVP ≈ MDPBP > α-PPP > MDPPP — all more effective reinforcers than cocaine (Gannon et al. 2017 [Ref 19])
- Reinforcing effectiveness directly correlates with DAT/SERT selectivity (Gannon et al. 2018 [Ref 5])
- Progressive ratio and behavioral economic measures confirm supranormal reinforcing efficacy vs. cocaine

### Reward Pathway Mechanism

α-PVP activates the reward pathway via CREB phosphorylation in the nucleus accumbens shell, consistent with classical stimulant addiction neuroscience (Hataoka et al. 2017 [Ref 37]). Drug history effects: ethanol pre-exposure differentially modifies α-PVP reward/aversion balance in rats (Nelson et al. 2021 [Ref 13]).

### Tolerance

The brief states buildup "develops with prolonged and repeated use" with a half-life of 5 days and full reset in 1.5 weeks. No published controlled study was found verifying these specific tolerance parameters for α-PVP in humans. **FLAG:** These values may be extrapolated from user reports or structural class inference (dopamine-based stimulant tolerance data). 

Neuroadaptive changes following repeated exposure are documented for related compounds (MDPV): DAT downregulation, ΔFosB induction, and CDK5 increases persisting post-withdrawal (Duart-Castells et al. 2019 — related compound data).

### Cross-Tolerance

The brief lists cross-tolerance with "dopamine, stimulant" class. This is consistent with shared DAT-inhibition mechanism and established stimulant cross-tolerance neuroscience — but no α-PVP-specific cross-tolerance study was found. **FLAG for generation agent: state as class inference.**

### Dependence

The brief classifies physical and psychological dependence as "high." Published preclinical data strongly supports high psychological dependence potential (self-administration, CPP studies). Physical dependence and withdrawal characterization in humans is absent from the published literature. The brief's characterization is supported by the reinforcing efficacy data but not confirmed by human withdrawal studies.

---

## Interactions

### Tramadol (listed as "lethal" in brief)

No published pharmacological study specifically characterizing the α-PVP–tramadol interaction was identified in this search. The "lethal" categorization in the brief requires **FLAG for editorial review** — the mechanism is pharmacologically plausible (tramadol inhibits serotonin/norepinephrine reuptake AND is a weak µ-opioid agonist; combined with α-PVP's norepinephrine reuptake inhibition, serotonin syndrome and cardiovascular toxicity risk increases), but no published case reports or animal studies specifically documenting this combination at lethal doses were found. This interaction severity is not supported by a specific published source in the current search.

### MDMA (listed as "dangerous")

No α-PVP + MDMA-specific published study found. Combined dopaminergic + serotonergic hyperstimulation creates risk of serotonin syndrome, severe hyperthermia, and cardiac toxicity — consistent with the general cathinone class interaction profile. **FLAG: mechanistic inference, not substance-specific published data.**

### Alcohol (listed as "unknown")

Animal data: Ethanol pre-exposure differentially modifies α-PVP reward/aversion in rats — ethanol history altered both rewarding and aversive effects of α-PVP (Nelson et al. 2021 [Ref 13]). The brief's "unknown" characterization is somewhat conservative — the direction and magnitude of human interaction is unknown, but preclinical interaction has been documented. **FLAG for generation agent.**

### Other Stimulants

α-PVP + MDPV mixture produced significantly greater locomotor activation than either drug alone, particularly in females (Shaykin & Baker 2024 [Ref 23]). However, α-PVP alone failed to produce conditioned place preference, while MDPV and the mixture did — suggesting additive pharmacodynamic interaction.

---

## Legal Status

### United States
- **Temporary Schedule I placement:** Effective February 27, 2014 (with 10 other synthetic cathinones; Federal Register January 28, 2014)
- **Permanent Schedule I placement:** Published March 1, 2017, Federal Register Vol. 82, No. 39 (82 FR 12171) [Ref 31]
- α-PVP is also covered under the Federal Analogue Act as a structural analog of cathinone (Schedule I)

### European Union
- EMCDDA Risk Assessment completed: November 2015
- EMCDDA-Europol Joint Report published: 2015 [Ref 32]
- EU Council Decision requiring all member states to implement control measures: June 27, 2016
- Most EU member states now have it as a controlled substance (varies by country)

### United Kingdom
- Covered as a psychoactive substance under the Psychoactive Substances Act 2016, effective May 26, 2016 [Ref 34]
- Sale, distribution, supply for human use is prohibited
- Not separately classified under Misuse of Drugs Act 1971 Class A/B/C system

### Australia
- TGA Schedule 9 (Prohibited Substance) — may only be used for research with a permit
- Effective April 2018 following final scheduling decision [Ref 33]
- Sale, manufacture, distribution, and use without permit strictly prohibited

### Canada
- Cathinone is listed as Schedule III under the Controlled Drugs and Substances Act (CDSA)
- α-PVP specific scheduling: unclear from published sources. May fall under analogue provisions as a derivative of cathinone. A 2017 amendment to CDSA regulations was identified (Canada Gazette 2017-02-22) but α-PVP-specific listing was not confirmed. **FLAG: Canada status should be verified against current Health Canada listings.**

### Japan
- Regulated as a designated substance following reports of traffic accidents involving α-PVP-impaired drivers by 2014–2015 (Hataoka et al. 2017 [Ref 37])

---

## Clinical Trials

No active, recruiting, or completed clinical trials for α-PVP were found on ClinicalTrials.gov. This is consistent with its Schedule I/prohibited status in most jurisdictions and the absence of any therapeutic development pathway.

The only published controlled human exposure data comes from naturalistic observational studies (De la Rosa et al. 2025 [Ref 1]; Di Trana et al. 2025 [Ref 2]) rather than formal clinical trials.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. No feedback items to evaluate.

---

## Gaps & Flags

### Safety-Critical Values Requiring Editorial Review

1. **⚠️ FLAG — Tramadol interaction severity ("lethal"):** No published primary source found documenting a lethal α-PVP + tramadol interaction specifically. Mechanism is pharmacologically plausible (NRI overlap + opioid receptor activity + seizure risk) but unverifiable from published data. Generation agent should note absence of specific evidence and label as precautionary/mechanism-based.

2. **⚠️ FLAG — LD50 / lethal dose range:** No published LD50 or minimum lethal dose for α-PVP. The brief correctly states "exact toxic dosage is unknown." Do not generate a numerical threshold without a citation.

3. **⚠️ FLAG — Tolerance half-life (5 days) and full reset (1.5 weeks):** These specific values were not confirmed against any published source. They should be labeled as community-consensus estimates, not pharmacokinetically derived data.

4. **⚠️ FLAG — SMILES string:** Not returned by the PubChem API call in this session. The SMILES for CID 11148955 should be fetched directly from PubChem before publication.

### Data Gaps

5. **No human oral or smoked PK data:** All published human PK is intranasal (Di Trana 2025 [Ref 2]). Duration values for oral and smoked routes are user-report-derived.

6. **No CYP enzyme characterization:** No published study identifies CYP enzymes responsible for α-PVP metabolism in humans. CYP3A4 is most probable based on class inference from pyrrolidine oxidation chemistry.

7. **No withdrawal characterization in humans:** Physical dependence and withdrawal syndrome in humans not published.

8. **Canada legal status:** Specific CDSA Schedule entry for α-PVP not confirmed in published sources. Should be verified via Health Canada's current controlled substances list.

9. **Original synthesis date/inventor:** Not confirmed from available published sources. The brief labels α-PVP as structurally related to pyrovalerone (1960s drug) but the specific synthesis date for α-PVP itself was not found.

10. **No bioavailability data:** Absolute bioavailability by any route in humans not published.

11. **MDMA and alcohol interaction severities:** Categorized as "dangerous" and "unknown" in the brief. These are supported by mechanism-based reasoning but not by α-PVP-specific published studies. Should be labeled as mechanistic inference.

12. **Conditioned place preference inconsistency:** Shaykin & Baker (2024 [Ref 23]) found α-PVP alone failed to produce CPP in rats, while Hataoka et al. (2017 [Ref 37]) found CPP with 25 mg/kg × 3 days. Dose and protocol differences likely explain this (Shaykin used 1 mg/kg; Hataoka used 25 mg/kg). Generation agent should note this and not present CPP as unambiguously established at typical doses.

### Contradictions with Seed Data

13. **PubChem CID, formula, weight, InChIKey:** All confirmed — the brief had empty fields for these but the compound identity is fully verified as C₁₅H₂₁NO, MW 231.33, CID 11148955.

14. **"Characterization: emerging":** Based on the publication record (40+ primary papers, human PK data, post-mortem concentration databases), α-PVP is no longer best described as "emerging" — it has an established literature base. However, this is an editorial classification decision, not a factual error.